Case number 1:21-cv-01736
Genzyme Corporation et al v. Novartis Gene Therapies, Inc. et al > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Feb 14, 2024 | 373 | STIPULATION of Dismissal with Prejudice, by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 2/14/2024 (nms). (Entered: 02/14/2024) (3) |
| Feb 14, 2024 | 374 | SO ORDERED Granting 373 Joint Stipulation of Dismissal with Prejudice (***Civil Case Terminated). Signed by Judge Richard G. Andrews on 2/14/2024. (nms) (Entered: 02/14/2024) (3) |
| Feb 14, 2024 | 375 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,596,535; 7,125,717; 7,785,888; 7,846,729; 8,093,054; 9,051,542. (Attachments: # 1 Order)(nms) (Entered: 02/14/2024) (0) |
| Feb 8, 2024 | 372 | REDACTED VERSION of 370 Letter by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 02/08/2024) (2) |
| Feb 1, 2024 | 370 | [SEALED] Joint Letter to The Honorable Richard G. Andrews, from the Parties, regarding request for temporary stay. (Joyce, Alexandra) Modified on 2/1/2024 (nms). (Entered: 02/01/2024) (0) |
| Feb 1, 2024 | 371 | ORAL ORDER: The request for a temporary stay and to cancel the hearing scheduled for 2/9/2024 (D.I 370 ) is GRANTED. Ordered by Judge Richard G. Andrews on 2/1/2024. (nms) (Entered: 02/01/2024) (0) |
| Jan 31, 2024 | 369 | NOTICE OF SERVICE of Expert Report of Mansoor Amiji, R.Ph., Ph.D filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 01/31/2024) (5) |
| Jan 29, 2024 | 367 | REDACTED VERSION of 362 Letter, by Aventis Inc., Genzyme Corporation. (Attachments: # 1 Exhibits 1-12)(Vavala, Donald) Modified on 1/29/2024 (nms). (Entered: 01/29/2024) (0) |
| Jan 29, 2024 | 368 | REDACTED VERSION of 363 Declaration of Martyn C. Davies, PH.D, by Aventis Inc., Genzyme Corporation. (Attachments: # 1 Exhibits 1-9, # 2 Exhibits 10-18)(Vavala, Donald) Modified on 1/29/2024 (nms). (Entered: 01/29/2024) (0) |
| Jan 24, 2024 | 364 | STIPULATION and Proposed Order to Extend Time to redacted versions of D.I. 362 and D.I. 363 to January 29, 2024 - filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 1/24/2024 (nms). (Entered: 01/24/2024) (2) |
| Jan 24, 2024 | 365 | Official Transcript of Discovery Dispute Conference held on 12/4/23 before Judge Richard G. Andrews. Court Reporter/Transcriber Heather M. Triozzi,Email: Heather_Triozzi@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 2/14/2024. Redacted Transcript Deadline set for 2/26/2024. Release of Transcript Restriction set for 4/23/2024. (Triozzi, Heather) (Entered: 01/24/2024) (56) |
| Jan 24, 2024 | 366 | Official Transcript of Discovery Dispute Conference held on 12/21/23 before Judge Richard G. Andrews. Court Reporter/Transcriber Heather M. Triozzi,Email: Heather_Triozzi@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 2/14/2024. Redacted Transcript Deadline set for 2/26/2024. Release of Transcript Restriction set for 4/23/2024. (Triozzi, Heather) (Entered: 01/24/2024) (33) |
| Jan 17, 2024 | 361 | ORAL ORDER: Oral argument for the Omnibus Motions for Summary Judgment and Exclusion of Expert Opinions (D.I. 296 ), Motion for Summary Judgment and to Exclude Expert Opinions (D.I. 295 ), and the supplemental claim construction is now set for 2/9/2024 at 9:00 AM in Courtroom 6A. Ordered by Judge Richard G. Andrews on 1/17/2024. (nms) (Entered: 01/17/2024) (0) |
| Jan 17, 2024 | 362 | [SEALED] Letter to the Honorable Richard G. Andrews, from D. Charles Vavala, regarding claim construction dispute. (Attachments: # 1 Exhibits 1-12, # 2 Certificate of Service)(Vavala, Donald) Modified on 1/18/2024 (nms). (Entered: 01/17/2024) (0) |
| Jan 17, 2024 | 363 | [SEALED] DECLARATION of Martyn C. Davies, PH.D. re 362 Letter, by Aventis Inc., Genzyme Corporation. (Attachments: # 1 Exhibits 1-9, # 2 Exhibits 10-18, # 3 Certificate of Service)(Vavala, Donald) Modified on 1/18/2024 (nms). (Entered: 01/17/2024) (0) |
| Jan 12, 2024 | 360 | MEMORANDUM ORDER: The motion for reargument and reconsideration (D.I. 269 ) is DENIED (see Memorandum Order for further details). Signed by Judge Richard G. Andrews on 1/12/2024. (nms) (Entered: 01/12/2024) (7) |
| Jan 5, 2024 | 357 | STIPULATION and [Proposed] Order Regarding Discovery on Novartis Inequitable Conduct and Unclean Hands Claims and Defenses by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 01/05/2024) (2) |
| Jan 5, 2024 | 358 | MOTION for Pro Hac Vice Appearance of Attorney L. Scott Burwell - filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation. (Attachments: # 1 Certification for L. Scott Burwell)(Joyce, Alexandra) (Entered: 01/05/2024) (0) |
| Jan 5, 2024 | 359 | Pro Hac Vice Fee - Credit Card Payment received for L. Scott Burwell. ( re 358 MOTION for Pro Hac Vice Appearance of Attorney L. Scott Burwell )( Payment of $ 50, receipt number ADEDC-4307599).(Joyce, Alexandra) (Entered: 01/05/2024) (0) |
| Jan 2, 2024 | 355 | NOTICE of Withdrawal of Pro Hac Vice Counsel James C. Gumina by Aventis Inc., Genzyme Corporation (Vavala, Donald) (Entered: 01/02/2024) (1) |
| Jan 2, 2024 | 356 | NOTICE OF SERVICE of (1) Third Party Roberta L. Robins Responses and Objections to Defendants Subpoenas to Produce Documents, Information, or Objects and (2) Third Party Gregory Bellomys Responses and Objections to Defendants Subpoenas to Produce Documents, Information, or Objects filed by Aventis Inc., Genzyme Corporation.(Vavala, Donald) (Entered: 01/02/2024) (4) |
| Dec 29, 2023 | 353 | REDACTED VERSION of 350 Letter, by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation. (Silver, Daniel) (Entered: 12/29/2023) (30) |
| Dec 29, 2023 | 354 | REDACTED VERSION of 351 Declaration, by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation. (Attachments: # 1 Part 2)(Silver, Daniel) Modified on 12/29/2023 (nms). (Entered: 12/29/2023) (0) |
| Dec 28, 2023 | 352 | NOTICE OF SERVICE of Plaintiffs' Objections and Responses to Defendants' Fourth Set of Requests for Production of Documents and Things Nos. 76-82 filed by Aventis Inc., Genzyme Corporation.(Vavala, Donald) (Entered: 12/28/2023) (3) |
| Dec 22, 2023 | 342 | REDACTED VERSION of 324 Answering Brief in Opposition, by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 12/22/2023) (30) |
| Dec 22, 2023 | 343 | REDACTED VERSION of 325 Declaration, by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibits 1-26)(Joyce, Alexandra) (Entered: 12/22/2023) (0) |
| Dec 22, 2023 | 344 | REDACTED VERSION of 329 Reply Brief, by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 12/22/2023) (30) |
| Dec 22, 2023 | 345 | REDACTED VERSION of 330 Declaration by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibits 31-37)(Joyce, Alexandra) (Entered: 12/22/2023) (0) |
| Dec 22, 2023 | 346 | REDACTED VERSION of 322 Answering Brief in Opposition, by Aventis Inc., Genzyme Corporation. (Vavala, Donald) (Additional attachment(s) added on 1/3/2024: # 1 Proposed Order, # 2 Certificate of Service) (nms). (Entered: 12/22/2023) (0) |
| Dec 22, 2023 | 347 | REDACTED VERSION of 323 Declaration by Aventis Inc., Genzyme Corporation. (Attachments: # 1 Exhibit 35-54, # 2 Exhibit 55-74)(Vavala, Donald) (Entered: 12/22/2023) (0) |
| Dec 22, 2023 | 348 | REDACTED VERSION of 331 Reply Brief by Aventis Inc., Genzyme Corporation. (Vavala, Donald) (Entered: 12/22/2023) (30) |
| Dec 22, 2023 | 349 | REDACTED VERSION of 332 Declaration by Aventis Inc., Genzyme Corporation. (Attachments: # 1 Exhibit 75-80, # 2 Exhibit 81-86)(Vavala, Donald) (Entered: 12/22/2023) (0) |
| Dec 22, 2023 | 350 | [SEALED] Letter to The Honorable Richard G. Andrews, from Daniel M. Silver, Esq., regarding Defendants' supplemental claim construction briefing. (Attachments: # 1 Exhibits 1-4, # 2 Certificate of Service)(Silver, Daniel) Modified on 12/26/2023 (nms). (Entered: 12/22/2023) (0) |
| Dec 22, 2023 | 351 | [SEALED] DECLARATION of Mansoor Amiji, R.Ph., Ph.D. re 350 Letter, by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibits A-M, # 2 Exhibits N-Z, # 3 Exhibit AA, # 4 Certificate of Service)(Silver, Daniel) Modified on 12/26/2023 (nms). (Entered: 12/22/2023) (0) |
| Dec 21, 2023 | 340 | REDACTED VERSION of 334 Letter by Aventis Inc., Genzyme Corporation. (Attachments: # 1 Exhibit 1-5)(Vavala, Donald) (Entered: 12/21/2023) (0) |
| Dec 21, 2023 | 341 | ORAL ORDER: The discovery issues discussed at the conference held 12/21/2023, are deemed resolved. The transcript will serve as the Order of the Court. Ordered by Judge Richard G. Andrews on 12/21/2023. (nms) (Entered: 12/21/2023) (0) |
| Dec 19, 2023 | 338 | SO ORDERED Granting 337 Stipulation and Proposed Order regarding deadlines and page limits for supplemental claim construction briefing (see Order for further details). Signed by Judge Richard G. Andrews on 12/19/2023. (nms) (Entered: 12/19/2023) (2) |
| Dec 19, 2023 | 339 | REDACTED VERSION of 333 Letter by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 12/19/2023) (30) |
| Dec 18, 2023 | 337 | STIPULATION and [Proposed] Order regarding supplemental claim construction briefing by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 12/18/2023) (2) |
| Dec 15, 2023 | 335 | REDACTED VERSION of 300 Declaration, by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30)(Joyce, Alexandra) Modified on 12/15/2023 (nms). (Entered: 12/15/2023) (0) |
| Dec 15, 2023 | 336 | REDACTED VERSION of 298 Declaration of Daniel Roberts, by Aventis Inc., Genzyme Corporation. (Attachments: # 1 Exhibits 1-11, # 2 Exhibits 12-22, # 3 Exhibits 23-34)(Vavala, Donald) Modified on 12/15/2023 (nms). (Entered: 12/15/2023) (0) |
| Dec 14, 2023 | 334 | [SEALED] Letter to the Honorable Richard G. Andrews, from D. Charles Vavala, regarding discovery dispute. (Attachments: # 1 Exhibits 1-5, # 2 Proposed Order, # 3 Certificate of Service)(Vavala, Donald) Modified on 12/14/2023 (nms). (Entered: 12/14/2023) (0) |
| Dec 12, 2023 | 329 | [SEALED] REPLY BRIEF re 296 MNIBUS Motions for Summary Judgment and Exclusion of Expert Opinions filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation. (Attachments: # 1 Certificate of Service)(Silver, Daniel) (Entered: 12/12/2023) (0) |
| Dec 12, 2023 | 330 | [SEALED] DECLARATION of Cora R. Holt re 329 Reply Brief, by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibits 31-37, # 2 Certificate of Service)(Silver, Daniel) Modified on 12/13/2023 (nms). (Entered: 12/12/2023) (0) |
| Dec 12, 2023 | 331 | [SEALED] REPLY BRIEF re 295 MOTION for Summary Judgment and to Exclude Expert Opinions filed by Aventis Inc., Genzyme Corporation. (Attachments: # 1 Certificate of Service)(Vavala, Donald) (Entered: 12/12/2023) (0) |
| Dec 12, 2023 | 332 | [SEALED] DECLARATION of Daniel Roberts re 331 Reply Brief, by Aventis Inc., Genzyme Corporation. (Attachments: # 1 Exhibits 75-80, # 2 Exhibits 81-86, # 3 Certificate of Service)(Vavala, Donald) Modified on 12/13/2023 (nms). (Entered: 12/12/2023) (0) |
| Dec 12, 2023 | 333 | [SEALED] Letter to The Honorable Richard G. Andrews, from Daniel M. Silver, regarding discovery dispute. (Attachments: # 1 Exhibits A-E, # 2 Proposed Order, # 3 Certificate of Service)(Silver, Daniel) Modified on 12/13/2023 (nms). (Entered: 12/12/2023) (0) |
| Dec 7, 2023 | 328 | STIPULATION and Proposed Order to Extend Time Regarding Certain Revised Redacted Versions of Sealed Filings - filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 12/7/2023 (nms). (Entered: 12/07/2023) (3) |
| Dec 6, 2023 | 327 | STIPULATION and [Proposed] Order Regarding Public Versions of the Parties' Motion for Summary Judgment Filings, by Aventis Inc., Genzyme Corporation. (Vavala, Donald) Modified on 12/6/2023 (nms). (Entered: 12/06/2023) (3) |
| Dec 5, 2023 | 326 | ORAL ORDER: The parties have advised that a dispute has arisen requiring judicial attention. The Court will hold a discovery conference on 12/21/2023, at 2:00 PM in Courtroom 6A. In preparation for this conference the parties shall follow the Discovery Matters and Disputes procedure as set forth in the Scheduling Order. Ordered by Judge Richard G. Andrews on 12/5/2023. (nms) (Entered: 12/05/2023) (0) |
| Dec 4, 2023 | 319 | REDACTED VERSION of 310 Letter, by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation. (Silver, Daniel) (Entered: 12/04/2023) (30) |
| Dec 4, 2023 | 320 | REDACTED VERSION of 309 Letter, by Aventis Inc., Genzyme Corporation. (Attachments: # 1 Exhibit 1-12)(Vavala, Donald) (Entered: 12/04/2023) (0) |
| Dec 4, 2023 | 321 | ORAL ORDER: The redacted filings at D.I. 313 and 316 are REJECTED because parts of them are redacted in entirety. Absent a compelling reason, supported by a statement under oath by a party, redactions in their entirety are impermissible; redactions must be done so as to redact the least possible amount of the materials submitted. Failure to make a good faith attempt at such redactions may result in sanctions, the most common of which would be simply unsealing the entire filing. Redacting in its entirety a document, or parts of it, that contains publicly available materials is prima facie evidence of bad faith. Revised redacted filings are DUE within five business days. Ordered by Judge Richard G. Andrews on 12/4/2023. (nms) (Entered: 12/04/2023) (0) |
| Dec 4, 2023 | 322 | [SEALED] ANSWERING BRIEF in Opposition re 296 MNIBUS Motions for Summary Judgment and Exclusion of Expert Opinions filed by Aventis Inc., Genzyme Corporation.Reply Brief due date per Local Rules is 12/11/2023. (Attachments: # 1 Proposed Order, # 2 Certificate of Service)(Vavala, Donald) (Entered: 12/04/2023) (0) |
| Dec 4, 2023 | 323 | [SEALED] DECLARATION re 322 Answering Brief in Opposition, by Aventis Inc., Genzyme Corporation. (Attachments: # 1 Exhibit 35-54, # 2 Exhibit 55-74, # 3 Certificate of Service)(Vavala, Donald) (Entered: 12/04/2023) (0) |
| Dec 4, 2023 | 324 | [SEALED] ANSWERING BRIEF in Opposition re 295 MOTION for Summary Judgment and to Exclude Expert Opinions filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation.Reply Brief due date per Local Rules is 12/11/2023. (Attachments: # 1 Certificate of Service)(Silver, Daniel) (Entered: 12/04/2023) (0) |
| Dec 4, 2023 | 325 | [SEALED] DECLARATION of Cora R. Holt re 324 Answering Brief in Opposition, by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibits 1-20, # 2 Exhibits 21-26, # 3 Certificate of Service)(Silver, Daniel) Modified on 12/4/2023 (nms). (Attachment 1 replaced on 12/5/2023) (nms). (Entered: 12/04/2023) (0) |
| Dec 1, 2023 | 312 | REDACTED VERSION of 299 Opening Brief in Support, by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 12/01/2023) (30) |
| Dec 1, 2023 | 313 | REDACTED VERSION of 300 Declaration, by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2-5, # 3 Exhibit 6, # 4 Exhibit 7-10, # 5 Exhibit 11-14, # 6 Exhibit 15-17, # 7 Exhibit 18, # 8 Exhibit 19-30)(Joyce, Alexandra) Modified on 12/1/2023 (nms). (Entered: 12/01/2023) (0) |
| Dec 1, 2023 | 314 | REDACTED VERSION of 304 Letter, by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 12/01/2023) (30) |
| Dec 1, 2023 | 315 | REDACTED VERSION of 297 Opening Brief in Support, by Aventis Inc., Genzyme Corporation. (Vavala, Donald) (Entered: 12/01/2023) (30) |
| Dec 1, 2023 | 316 | REDACTED VERSION of 298 Declaration of Daniel Roberts, by Aventis Inc., Genzyme Corporation. (Attachments: # 1 Exhibits 1-11, # 2 Exhibits 12-22, # 3 Exhibits 23-34)(Vavala, Donald) Modified on 12/1/2023 (nms). (Entered: 12/01/2023) (0) |
| Dec 1, 2023 | 317 | REDACTED VERSION of 302 Answer to Counterclaim by Aventis Inc., Genzyme Corporation. (Attachments: # 1 Exhibit A-F)(Vavala, Donald) (Entered: 12/01/2023) (0) |
| Dec 1, 2023 | 318 | REDACTED VERSION of 305 Letter, by Aventis Inc., Genzyme Corporation. (Attachments: # 1 Exhibit 1-7, # 2 Exhibit 8-14, # 3 Text of Proposed Order)(Vavala, Donald) (Entered: 12/01/2023) (0) |
| Nov 27, 2023 | 306 | NOTICE OF SERVICE of Subpoenas Directed to Third Party Roberta L. Robins filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation.(Silver, Daniel) (Entered: 11/27/2023) (30) |
| Nov 27, 2023 | 307 | NOTICE OF SERVICE of Subpoenas Directed to Third Party Gregory R. Bellomy filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation.(Silver, Daniel) (Entered: 11/27/2023) (30) |
| Nov 27, 2023 | 308 | STIPULATION TO EXTEND TIME to file redacted versions of DI 304 and DI 305 to December 1, 2023 - filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 11/27/2023) (2) |
| Nov 27, 2023 | 309 | [SEALED] Letter to the Honorable Richard G. Andrews, from D. Charles Vavala, regarding response to Novartis' request to strike portions of expert Dr. Chamberlain's rebuttal report (D.I. 304). (Attachments: # 1 Exhibits 1-12, # 2 Certificate of Service)(Vavala, Donald) Modified on 11/28/2023 (nms). (Attachment 1 replaced on 11/29/2023) (nms). (Entered: 11/27/2023) (0) |
| Nov 27, 2023 | 310 | [SEALED] Letter to The Honorable Richard G. Andrews, from Daniel M. Silver, regarding opposition to Plaintiffs' request to strike. (Attachments: # 1 Exhibits A-I, # 2 Proposed Order, # 3 Certificate of Service)(Silver, Daniel) Modified on 11/28/2023 (nms). (Entered: 11/27/2023) (0) |
| Nov 27, 2023 | 311 | PROPOSED Order re 309 Letter, by Aventis Inc., Genzyme Corporation. (Vavala, Donald) Modified on 11/28/2023 (nms). (Entered: 11/27/2023) (1) |
| Nov 21, 2023 | 303 | STIPULATION and Proposed Order to Extend Time file redacted versions of D.I. 297, 298), 299, 300, and 302 to December 1, 2023 - filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 11/21/2023 (nms). (Entered: 11/21/2023) (2) |
| Nov 21, 2023 | 304 | [SEALED] Letter to The Honorable Richard G. Andrews, from Daniel M. Silver, regarding motion to strike portions of Ppaintiffs' expert Dr. Chamberlain's rebuttal report. (Attachments: # 1 Exhibits 1-3, # 2 Proposed Order, # 3 Certificate of Service)(Silver, Daniel) Modified on 11/21/2023 (nms). (Entered: 11/21/2023) (0) |
| Nov 21, 2023 | 305 | [SEALED] Letter to the Honorable Richard G. Andrews, from D. Charles Vavala, regarding discovery dispute. (Attachments: # 1 Exhibits 1-7, # 2 Exhibits 8-14, # 3 Proposed Order, # 4 Certificate of Service)(Vavala, Donald) Modified on 11/21/2023 (nms). (Attachment 2 replaced on 11/27/2023) (nms). (Entered: 11/21/2023) (0) |
| Nov 20, 2023 | 301 | REDACTED VERSION of 287 Amended Answer to Complaint,, Counterclaim, by Aventis Inc., Genzyme Corporation. (Attachments: # 1 Exhibit 1-8)(Vavala, Donald) (Entered: 11/20/2023) (0) |
| Nov 20, 2023 | 302 | [SEALED] ANSWER to 287 Amended Answer to Complaint,, Counterclaim, by Aventis Inc., Genzyme Corporation. (Attachments: # 1 Exhibit A-F, # 2 Certificate of Service)(Vavala, Donald) (Entered: 11/20/2023) (0) |
| Nov 17, 2023 | 295 | MOTION for Summary Judgment and to Exclude Expert Opinions - filed by Aventis Inc., Genzyme Corporation. (Attachments: # 1 Proposed Order)(Vavala, Donald) Modified on 11/20/2023 (nms). (Entered: 11/17/2023) (0) |
| Nov 17, 2023 | 296 | OMNIBUS Motions for Summary Judgment and Exclusion of Expert Opinions - filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation. (Attachments: # 1 Certification of Counsel, # 2 Proposed Order)(Joyce, Alexandra) Modified on 11/20/2023 (nms). (Entered: 11/17/2023) (0) |
| Nov 17, 2023 | 297 | [SEALED] OPENING BRIEF in Support re 295 MOTION for Summary Judgment and to Exclude Expert Opinions, filed by Aventis Inc., Genzyme Corporation.Answering Brief/Response due date per Local Rules is 12/1/2023. (Attachments: # 1 7.1.1 Certificate, # 2 Certificate of Service)(Vavala, Donald) Modified on 11/20/2023 (nms). (Entered: 11/17/2023) (0) |
| Nov 17, 2023 | 298 | [SEALED] DECLARATION of Daniel Roberts re 295 MOTION for Summary Judgment and to Exclude Expert Opinions, by Aventis Inc., Genzyme Corporation. (Attachments: # 1 Exhibits 1-11, # 2 Exhibits 12-22, # 3 Exhibits 23-34, # 4 Certificate of Service)(Vavala, Donald) Modified on 11/20/2023 (nms). Modified on 11/20/2023 (nms). (Entered: 11/17/2023) (0) |
| Nov 17, 2023 | 299 | [SEALED] OPENING BRIEF in Support re 296 OMNIBUS Motions for Summary Judgment and Exclusion of Expert Opinions, filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation. Answering Brief/Response due date per Local Rules is 12/1/2023. (Attachments: # 1 Certificate of Service)(Joyce, Alexandra) Modified on 11/20/2023 (nms). (Entered: 11/17/2023) (0) |
| Nov 17, 2023 | 300 | [SEALED] DECLARATION of Matthew Luneack, Esq. re 299 Opening Brief in Support, by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Certificate of Service)(Joyce, Alexandra) Modified on 11/20/2023 (nms). (Entered: 11/17/2023) (0) |
| Nov 16, 2023 | 293 | STIPULATION and [Proposed] Order by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 11/16/2023) (5) |
| Nov 16, 2023 | 294 | SO ORDERED Granting 293 Stipulation and Proposed Order. Signed by Judge Richard G. Andrews on 11/16/2023. (nms) (Entered: 11/16/2023) (5) |
| Nov 14, 2023 | 292 | STIPULATION and [Proposed] Order regarding Plaintiffs Answer to Defendants Amended Counterclaims, by Aventis Inc., Genzyme Corporation. (Vavala, Donald) Modified on 11/14/2023 (nms). (Entered: 11/14/2023) (3) |
| Nov 13, 2023 | 290 | ORAL ORDER: The redacted filing (D.I. 289 ) is REJECTED because parts of it are redacted in its entirety. Absent a compelling reason, supported by a statement under oath by a party, redactions in their entirety are impermissible; redactions must be done so as to redact the least possible amount of the materials submitted. Failure to make a good faith attempt at such redactions may result in sanctions, the most common of which would be simply unsealing the entire filing. Redacting in its entirety a document, or parts of it, that contains publicly available materials is prima facie evidence of bad faith. A revised redacted filing is DUE within five business days. Ordered by Judge Richard G. Andrews on 11/13/2023. (nms) (Entered: 11/13/2023) (0) |
| Nov 13, 2023 | 291 | NOTICE OF SERVICE of (1) Novartis Gene Therapies, Inc., and Novartis Pharmaceuticals Corporation's Sixth Set of Interrogatories to Plaintiffs (Nos. 26-29), and (2) Novartis Gene Therapies, Inc., and Novartis Pharmaceuticals Corporation's Fourth Set of Request for Production of Documents and Things (Nos. 76-82) filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 11/13/2023) (5) |
| Nov 10, 2023 | 289 | REDACTED VERSION of 287 Amended Answer to Complaint,, Counterclaim, by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 11/10/2023) (30) |
| Nov 6, 2023 | 288 | ORAL ORDER: The parties have advised that disputes have arisen requiring judicial attention. The Court will hold a discovery conference on 12/4/2023, at 3:30 PM in Courtroom 6A. In preparation for this conference the parties shall follow the Discovery Matters and Disputes procedure as set forth in the Scheduling Order. Ordered by Judge Richard G. Andrews on 11/6/2023. (nms) (Entered: 11/06/2023) (0) |
| Nov 2, 2023 | 287 | [SEALED] First Amended Answer, Defenses and Counterclaims to 17 Amended Complaint, by Novartis Gene Therapies, Inc. and Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Certificate of Service)(Joyce, Alexandra) Modified on 11/2/2023 (nms). (Entered: 11/02/2023) (0) |
| Nov 1, 2023 | 286 | ORAL ORDER. Having reviewed Defendants' Motion for Leave to File Amended Answer and Counterclaims, and the related briefing (D.I. 240, 255, 260), and having held a teleconference on November 1, 2023, IT IS HEREBY ORDERED that Defendants motion is GRANTED. The transcript of the November 1, 2023 teleconference contains the Court's rationale and further details regarding the Court's ruling. Motion for Leave to File Amended Answer and Counterclaims filed by Novartis Pharmaceuticals Corporation, Novartis Gene Therapies, Inc. Ordered by Judge Laura D. Hatcher on 11/1/23. (kjk) (Entered: 11/01/2023) (0) |
| Oct 31, 2023 | 285 | NOTICE to Take Deposition of Shauna L. Wiest on November 6, 2023 filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation.(Silver, Daniel) (Entered: 10/31/2023) (2) |
| Oct 27, 2023 | 284 | ORAL ORDER: The discovery conference scheduled for November 7, 2023, is CANCELED. The parties have advised chambers via email that dispute has been resolved. Ordered by Judge Richard G. Andrews on 10/27/2023. (nms) (Entered: 10/27/2023) (0) |
| Oct 26, 2023 | 283 | ORAL ORDER Setting Teleconference: A teleconference on the pending Motion for Leave to File Amended Answer and Counterclaims (D.I. 239) is scheduled for Wednesday, November 1, 2023 at 11:00am. Counsel shall send dial-in information directly to the Court, no later than 24 hours prior to the hearing, using the following e-mail address: keith_kincaid@ded.uscourts.gov.Ordered by Judge Laura D. Hatcher on 10/26/23. (kjk) (Entered: 10/26/2023) (0) |
| Oct 17, 2023 | 282 | NOTICE OF SERVICE of (1) Reply Expert Report of Mansoor Amini, Ph.D., (2) Reply Expert Report of Michael S. Kinch, Ph.D., (3) Reply Expert Report of Ewa Folta-Stogniew, Ph.D., (4) Reply Expert Report of Mark Kay, M.D., Ph.D., and (5) Reply Expert Report of Richard J. Samulski, Ph.D. filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 10/17/2023) (5) |
| Oct 16, 2023 | 281 | NOTICE OF SERVICE of (1) Reply Expert Declaration of S. Russ Lehrman; (2) Reply Expert Report of Matthew D. Weitzman, Ph.D. Regarding the Infringement of the Carter 054 Patent; (3) Reply Expert Declaration of Bruce A. Kerwin, Ph.D. Regarding Infringement, and (4) Reply Expert Report of Matthew R. Lynde, Ph.D. filed by Aventis Inc., Genzyme Corporation.(Vavala, Donald) (Entered: 10/16/2023) (4) |
| Oct 12, 2023 | 279 | STIPULATION and Proposed Order to Extend Time - filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 10/12/2023 (nms). (Entered: 10/12/2023) (3) |
| Oct 12, 2023 | 280 | SO ORDERED as modified re 279 STIPULATION and Proposed Order to Extend Time (*Reset Deadlines: Expert Discovery due by 11/10/2023, Dispositive Motions due by 11/17/2023, Responses due by 12/4/2023, Replies due by 12/12/2023). Signed by Judge Richard G. Andrews on 10/12/2023. (nms) (Entered: 10/12/2023) (3) |
| Oct 10, 2023 | 278 | ORAL ORDER: The parties have advised that a dispute has arisen requiring judicial attention. The Court will hold a discovery conference on 11/7/2023, at 3:00 PM in Courtroom 6A. In preparation for this conference the parties shall follow the Discovery Matters and Disputes procedure as set forth in the Scheduling Order. Ordered by Judge Richard G. Andrews on 10/10/2023. (nms) (Entered: 10/10/2023) (0) |
| Oct 4, 2023 | 277 | ORAL ORDER: The Motion for Leave to File Amended Answer and Counterclaims (D.I. 239 ) is now REFERRED to Magistrate Judge Laura D. Hatcher. Ordered by Judge Richard G. Andrews on 10/4/2023. (nms) (Entered: 10/04/2023) (0) |
| Sep 28, 2023 | 275 | NOTICE of Withdrawal of Pro Hac Vice Counsel Daniel Gonzalez, Jr. by Aventis Inc., Genzyme Corporation (Czerwonka, Scott) (Entered: 09/28/2023) (2) |
| Sep 28, 2023 | 276 | MOTION for Pro Hac Vice Appearance of Attorney Matthew L. Luneack - filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 09/28/2023) (4) |
| Sep 26, 2023 | 274 | NOTICE OF SERVICE of (1) Expert Report of Michael S. Kinch, Ph.D. with Appendices A-D; (2) Rebuttal Expert Report of Ewa Folta-Stogniew, Ph.D. with Appendix A; (3) Rebuttal Expert Report of Mark Kay, M.D., Ph.D. with Appendix C; (4) Expert Report of Anupam B. Jena, M.D., Ph.D. with Appendices A-C; and (5) Rebuttal Expert Report of Christopher A. Vellturo, Ph.D. with Exhibits 1-16 and Appendix filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 09/26/2023) (5) |
| Sep 25, 2023 | 273 | NOTICE OF SERVICE of (1) Expert Declaration of Martyn C. Davies, PH.D Regarding Validity; (2) Expert Report of James Dowling, M.D., PH.D.; (3) Expert Report of Jeffrey S. Chamberlain, PH.D. Regarding Validity of U.S. Patent No. 8,093,054; (4) Expert Report of Luk H. Vandenberghe, PH.D. Regarding the Validity of U.S. Patent NO. 8,093,054; (5) Expert Report of Matthew R. Lynde, PH.D filed by Aventis Inc., Genzyme Corporation.(Vavala, Donald) (Entered: 09/25/2023) (4) |
| Sep 15, 2023 | 272 | RESPONSE to 269 MOTION for Reargument and Reconsideration of Court's Indefiniteness Ruling on the "Enhanced Expression" Terms (D.I. 263 ), filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 9/15/2023 (nms). (Entered: 09/15/2023) (14) |
| Sep 6, 2023 | 270 | NOTICE OF SERVICE of Subpoena directed to Richard Jude Samulski filed by Aventis Inc., Genzyme Corporation.(Vavala, Donald) (Entered: 09/06/2023) (4) |
| Sep 6, 2023 | 271 | NOTICE of Denials of Institution of Inter Partes Review by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation (Attachments: # 1 Exhibit A, # 2 Exhibit B)(Joyce, Alexandra) (Entered: 09/06/2023) (0) |
| Sep 1, 2023 | 269 | MOTION for Reargument and Reconsideration of Court's Indefiniteness Ruling on the "Enhanced Expression" Terms (D.I. 263 ) - filed by Aventis Inc., Genzyme Corporation. (Attachments: # 1 Proposed Order, # 2 7.1.1 Certification)(Wilks, David) Modified on 9/1/2023 (nms). (Entered: 09/01/2023) (0) |
| Aug 30, 2023 | 268 | CLAIM CONSTRUCTION ORDER. Signed by Judge Richard G. Andrews on 8/30/2023. (nms) (Entered: 08/30/2023) (8) |
| Aug 28, 2023 | 267 | NOTICE OF SERVICE of (1) Opening Expert Report of Dr. Mark Kay, M.D., Ph.D. Regarding Invalidity of U.S. Patent No. 8,093,054 and Appendices A-B, (2) Opening Expert Report of Mansoor Amiji, R.Ph., Ph.D. and Exhibits A-B, (3) Opening Expert Report of Ewa Folta-Stongniew, Ph.D., Regarding Invalidity of U.S. Patent No. 9,051,542 Under 35 U.S.C. § 112 and Appendices A-B, and (4) Opening Expert Report of Dr. R. Jude Samulski, Ph.D. Regarding Invalidity of U.S. Patent No. 8,093,054 filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 08/28/2023) (5) |
| Aug 25, 2023 | 266 | NOTICE OF SERVICE of (1) Expert Declaration of Bruce A. Kerwin, Ph.D. Regarding Infringement, (2) Expert Declaration of S. Russ Lehrman, (3) Expert Report of Matthew D. Weitzman, Ph.D. Regarding Infringement of the Carter 054 Patent, and (4) Expert Report of Matthew R. Lynde, Ph.D filed by Aventis Inc., Genzyme Corporation.(Vavala, Donald) (Entered: 08/25/2023) (4) |
| Aug 23, 2023 | 265 | Letter to the Honorable Richard G. Andrews, from Scott B. Czerwonka, regarding certain discrepancies in the recently issued claim construction Memorandum Opinion. (Attachments: # 1 Proposed Claim Construction Order)(Czerwonka, Scott) Modified on 8/23/2023 (nms). (Entered: 08/23/2023) (0) |
| Aug 21, 2023 | 264 | STIPULATION and Proposed Order to Extend Time - filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 8/21/2023 (nms). (Entered: 08/21/2023) (3) |
| Aug 18, 2023 | 263 | MEMORANDUM OPINION: Providing claim construction for multiple terms in U.S. Patent Nos. 6,596,535, 7,125,717, 7,785,888, 7,846,729, 8,093,054, and 9,051,542. Within five days the parties shall submit a proposed order consistent with this Memorandum Opinion. Signed by Judge Richard G. Andrews on 8/18/2023. (nms) (Entered: 08/18/2023) (26) |
| Aug 11, 2023 | 262 | REDACTED VERSION of 260 Reply Brief, by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation. (Silver, Daniel) (Entered: 08/11/2023) (30) |
| Aug 8, 2023 | 261 | REDACTED VERSION of 249 Letter, by Aventis Inc., Genzyme Corporation. (Attachments: # 1 Exhibits 1-14, # 2 Proposed Order)(Czerwonka, Scott) Modified on 8/8/2023 (nms). (Entered: 08/08/2023) (0) |
| Aug 4, 2023 | 259 | REDACTED VERSION of 255 Answering Brief in Opposition, by Aventis Inc., Genzyme Corporation. (Czerwonka, Scott) Modified on 8/4/2023 (nms). (Entered: 08/04/2023) (24) |
| Aug 4, 2023 | 260 | [SEALED] REPLY BRIEF re 239 Motion for Leave to File Amended Answer and Counterclaims filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibits 24-25, # 2 Certificate of Service)(Silver, Daniel) (Entered: 08/04/2023) (0) |
| Aug 3, 2023 | 258 | ORAL ORDER: The redacted filing (D.I. 257 ) is REJECTED as it is not a complete version (i.e. original pdf for exhibits was 97 pages, and the redacted version is 96 pages) and parts of it are redacted in its entirety. Absent a compelling reason, supported by a statement under oath by a party, redactions in their entirety are impermissible; redactions must be done so as to redact the least possible amount of the materials submitted. Failure to make a good faith attempt at such redactions may result in sanctions, the most common of which would be simply unsealing the entire filing. Redacting in its entirety a document or parts of it that contains publicly available materials is prima facie evidence of bad faith. A revised redacted filings is DUE within five business days. Ordered by Judge Richard G. Andrews on 8/3/2023. (nms) (Entered: 08/03/2023) (0) |
| Aug 2, 2023 | 256 | REDACTED VERSION of 242 Letter, by Aventis Inc., Genzyme Corporation. (Attachments: # 1 Appendix A, # 2 Exhibits 1-21, # 3 Proposed Order)(Czerwonka, Scott) Modified on 8/2/2023 (nms). (Entered: 08/02/2023) (0) |
| Aug 2, 2023 | 257 | REDACTED VERSION of 249 Letter, by Aventis Inc., Genzyme Corporation. (Attachments: # 1 Exhibits 1-14, # 2 Proposed Order)(Czerwonka, Scott) Modified on 8/2/2023 (nms). (Entered: 08/02/2023) (0) |
| Jul 28, 2023 | 255 | [SEALED] ANSWERING BRIEF in Opposition re 239 Motion for Leave to File Amended Answer and Counterclaims filed by Aventis Inc., Genzyme Corporation.Reply Brief due date per Local Rules is 8/4/2023. (Attachments: # 1 Certificate of Service)(Czerwonka, Scott) (Entered: 07/28/2023) (0) |
| Jul 27, 2023 | 252 | STIPULATION and [Proposed] Order to Extend deadline to file redacted versions of (D.I. 242 ) and (D.I. 249 ) to 8/2/2023, by Aventis Inc., Genzyme Corporation. (Czerwonka, Scott) Modified on 7/27/2023 (nms). (Entered: 07/27/2023) (3) |
| Jul 27, 2023 | 253 | ORAL ORDER: The discovery conference scheduled for 7/31/2023, is CANCELED. The parties have advised the dispute has been resolved. Ordered by Judge Richard G. Andrews on 7/27/2023. (nms) (Entered: 07/27/2023) (0) |
| Jul 27, 2023 | 254 | STIPULATION and Proposed Order to Extend Discovery Deadlines - filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 7/27/2023 (nms). (Entered: 07/27/2023) (3) |
| Jul 26, 2023 | 250 | REDACTED VERSION of 239 Motion for Leave to File Amended Answer and Counterclaims by Aventis Inc., Genzyme Corporation. (Attachments: # 1 Exhibit A - B)(Czerwonka, Scott) (Entered: 07/26/2023) (0) |
| Jul 26, 2023 | 251 | REDACTED VERSION of 240 Opening Brief in Support, by Aventis Inc., Genzyme Corporation. (Attachments: # 1 Exhibits 1-23)(Czerwonka, Scott) Modified on 7/26/2023 (nms). (Entered: 07/26/2023) (0) |
| Jul 24, 2023 | 249 | [SEALED] Letter to the Honorable Richard G. Andrews, from Scott B.Czerwonka, regarding opposition to Defendants' letter raising a discovery dispute (D.I. 242 ). (Attachments: # 1 Exhibits 1-14, # 2 Proposed Order, # 3 Certificate of Service)(Czerwonka, Scott) Modified on 7/25/2023 (nms). (Entered: 07/24/2023) (0) |
| Jul 21, 2023 | 244 | SO ORDERED Granting 243 Stipulation and Proposed Order Regarding Motion to Amend (*Reset Briefing Schedule: re 239 Motion for Leave to File Amended Answer and Counterclaims. Answering Brief due 7/28/2023, Reply Brief due 8/4/2023). Signed by Judge Richard G. Andrews on 7/21/2023. (nms) (Entered: 07/21/2023) (3) |
| Jul 21, 2023 | 245 | NOTICE of Withdrawal of Subpoena served upon Kevin Foust by Aventis Inc., Genzyme Corporation (Czerwonka, Scott) (Entered: 07/21/2023) (3) |
| Jul 21, 2023 | 246 | NOTICE of Withdrawal of Third Party Subpoena and Notice of Deposition to Kevin Foust by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation (Joyce, Alexandra) (Entered: 07/21/2023) (3) |
| Jul 21, 2023 | 247 | NOTICE OF SERVICE of Defendants' Fourth Supplemental Rule 26(a)(1)(A) Disclosures filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 07/21/2023) (5) |
| Jul 21, 2023 | 248 | STIPULATION and Proposed Order to file redacted versions of Motion to Amend and Opening Brief in support thereof (Docket Nos. 239 - 240 ) to July 26, 2023 - filed by Aventis Inc., Genzyme Corporation. (Czerwonka, Scott) Modified on 7/24/2023 (nms). (Entered: 07/21/2023) (2) |
| Jul 20, 2023 | 242 | [SEALED] Letter to The Honorable Richard G. Andrews from Daniel M. Silver regarding Discovery Dispute. (Attachments: # 1 Proposed Order, # 2 Exhibits 1-21, # 3 Certificate of Service)(Silver, Daniel) (Entered: 07/20/2023) (0) |
| Jul 20, 2023 | 243 | STIPULATION and [Proposed] Order Regarding Defendants' Motion to Amend by Aventis Inc., Genzyme Corporation. (Czerwonka, Scott) (Entered: 07/20/2023) (3) |
| Jul 18, 2023 | 241 | STIPULATION and [Proposed] Order to Amend Case Schedule by Aventis Inc., Genzyme Corporation. (Wilks, David) (Entered: 07/18/2023) (3) |
| Jul 13, 2023 | 239 | [SEALED] Motion for Leave to File Amended Answer and Counterclaims - filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 7.1.1 Certification, # 4 Proposed Order, # 5 Certificate of Service)(Joyce, Alexandra) Modified on 7/14/2023 (nms). (Entered: 07/13/2023) (0) |
| Jul 13, 2023 | 240 | [SEALED] OPENING BRIEF in Support re 239 Motion for Leave to File Amended Answer and Counterclaims filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation.Answering Brief/Response due date per Local Rules is 7/27/2023. (Attachments: # 1 Exhibits 1-23, # 2 Certificate of Service)(Joyce, Alexandra) Modified on 7/14/2023 (nms). (Entered: 07/13/2023) (0) |
| Jul 12, 2023 | 238 | ORAL ORDER: The parties have advised that a dispute has arisen requiring attention. The Court will hold a conference on 7/31/2023, at 3:00 PM in Courtroom 6A. In preparation for this conference the parties shall follow the Discovery Matters and Disputes procedure as set forth in the Scheduling Order. Further, both sides are requested to attach proposed orders with their letters. Ordered by Judge Richard G. Andrews on 7/12/2023. (nms) (Entered: 07/12/2023) (0) |
| Jul 7, 2023 | 237 | NOTICE of Inter Partes Review of U.S. Patent No. 9,051,542 and Invalidity Grounds, by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit A)(Joyce, Alexandra) Modified on 7/10/2023 (nms). (Entered: 07/07/2023) (0) |
| Jul 5, 2023 | 236 | SO ORDERED Granting 234 Stipulation and Proposed Order to Complete Depositions After the Fact Discovery Deadline. Signed by Judge Richard G. Andrews on 7/5/2023. (nms) (Entered: 07/05/2023) (3) |
| Jul 3, 2023 | 235 | NOTICE OF SERVICE of Plaintiffs Objections and Fourth Supplemental Response to Defendants Interrogatory (No. 14) filed by Aventis Inc., Genzyme Corporation.(Czerwonka, Scott) (Entered: 07/03/2023) (4) |
| Jun 30, 2023 | 232 | NOTICE OF SERVICE of Plaintiffs Objections and Responses to Defendants First Set of Requests for Admissions (Nos. 1-50) filed by Aventis Inc., Genzyme Corporation.(Czerwonka, Scott) (Entered: 06/30/2023) (4) |
| Jun 30, 2023 | 233 | NOTICE OF SERVICE of (1) Defendant' First Supplemental Objections and Responses to Interrogatories Nos. 16, 18, 19, and 23, and (2) Defendants' Responses and Objections to Plaintiffs' Fourth Set of Interrogatories (Nos. 24-25) filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 06/30/2023) (5) |
| Jun 30, 2023 | 234 | STIPULATION and [Proposed] Order to Complete Depositions After The Fact Discovery Deadline by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 06/30/2023) (3) |
| Jun 29, 2023 | 231 | NOTICE OF SERVICE of Subpoena to Kevin Foust filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 06/29/2023) (6) |
| Jun 26, 2023 | 228 | NOTICE to Take Deposition of Monica Bennett on July 10, 2023 filed by Aventis Inc., Genzyme Corporation.(Wilks, David) (Entered: 06/26/2023) (2) |
| Jun 26, 2023 | 229 | NOTICE OF SERVICE of Defendants' First Supplemental Objection and Response to Plaintiffs' Interrogatory No. 2 and Second Supplemental Objection and Response to Plaintiffs' Interrogatory No. 1 filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation.(Silver, Daniel) (Entered: 06/26/2023) (5) |
| Jun 26, 2023 | 230 | NOTICE OF SERVICE of (1) Plaintiffs Objections and Second Supplemental Responses to Defendants Third Set of Interrogatories No. 16; (2) Plaintiffs Objections and Third Supplemental Response to Defendants Interrogatory No. 14; (3) Plaintiffs Objections and First Supplemental Responses to Defendants Interrogatories (Nos. 1, 4, 11) and Objections and Second Supplemental Responses to Defendants Interrogatories (Nos. 2-3, 5-10, 12-13); and (4) Plaintiffs Objections and First Supplemental Responses to Defendants Fourth Set of Interrogatories (Nos. 17-19) filed by Aventis Inc., Genzyme Corporation.(Czerwonka, Scott) (Entered: 06/26/2023) (4) |
| Jun 21, 2023 | 227 | NOTICE OF SERVICE of Plaintiffs Objections and Responses to Defendants Fifth Set of Interrogatories to Plaintiffs (Nos. 20-25) filed by Aventis Inc., Genzyme Corporation.(Czerwonka, Scott) (Entered: 06/21/2023) (4) |
| Jun 20, 2023 | 224 | MOTION for Pro Hac Vice Appearance of Attorney D. Brian Kacedon - filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation. (Silver, Daniel) (Entered: 06/20/2023) (3) |
| Jun 20, 2023 | 225 | [SEALED] ORDER Granting 219 STIPULATION and [Proposed] Order Regarding The Definition of Zolgensma. Signed by Judge Richard G. Andrews on 6/20/2023.*This order has been emailed to local counsel. (nms) (Entered: 06/20/2023) (0) |
| Jun 20, 2023 | 226 | REDACTED VERSION of 219 Stipulation and [Proposed] Order Regarding the Definition of Zolgensma, by Aventis Inc., Genzyme Corporation. (Czerwonka, Scott) Modified on 6/20/2023 (nms). (Entered: 06/20/2023) (4) |
| Jun 16, 2023 | 221 | NOTICE OF SERVICE of Subpoena for Deposition Testimony Directed to Third Party Shangzhen Zhou filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 06/16/2023) (22) |
| Jun 16, 2023 | 222 | NOTICE OF SERVICE of Subpoena for Deposition Testimony Directed to Third Party Jurg M. Sommer filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 06/16/2023) (22) |
| Jun 16, 2023 | 223 | NOTICE OF SERVICE of (1) Defendants Second Amended Invalidity Contentions Regarding U.S. Patent Nos. 6,596,535, 7,125,717, 7,785,888, 7,846,729, 8,093,054, and 9,051,542, and (2) Defendants First Supplemental Objections and Responses to Plaintiffs Interrogatories Nos. 3 and 7 and Second Supplemental Objections and Responses to Plaintiffs Interrogatories Nos. 6-7 and 10-12 filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 06/16/2023) (4) |
| Jun 15, 2023 | 220 | NOTICE to Take Deposition of Peter Waibel on June 23, 2023 filed by Aventis Inc., Genzyme Corporation.(Czerwonka, Scott) (Entered: 06/15/2023) (2) |
| Jun 13, 2023 | 219 | [SEALED] STIPULATION and [Proposed] Order Regarding The Definition of Zolgensma by Aventis Inc., Genzyme Corporation. (Attachments: # 1 Certificate of Service)(Czerwonka, Scott) (Entered: 06/13/2023) (0) |
| Jun 12, 2023 | 217 | NOTICE to Take Deposition of Joshua Prabhakar on June 16, 2023 filed by Aventis Inc., Genzyme Corporation.(Czerwonka, Scott) (Entered: 06/12/2023) (2) |
| Jun 12, 2023 | 218 | MOTION for Pro Hac Vice Appearance of Attorney Amy Fulton, Yieyie Yang, and Jeffrey Smyth - filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation. (Silver, Daniel) (Entered: 06/12/2023) (5) |
| Jun 9, 2023 | 215 | REDACTED VERSION of 173 Notice to Take Deposition, by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 06/09/2023) (21) |
| Jun 9, 2023 | 216 | NOTICE OF SERVICE of Plaintiffs Objections and Second Supplemental Responses to Defendants Interrogatories Nos. 10 and 14 filed by Aventis Inc., Genzyme Corporation.(Czerwonka, Scott) (Entered: 06/09/2023) (4) |
| Jun 8, 2023 | 212 | NOTICE OF SERVICE of Subpoena for Deposition Testimony Directed to Third Party Kathryn Loomis Rogers filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 06/08/2023) (6) |
| Jun 8, 2023 | 213 | NOTICE OF SERVICE of Defendants' Third Supplemental Rule 26(a)(1)(A) Disclosures filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 06/08/2023) (4) |
| Jun 8, 2023 | 214 | NOTICE to Take Deposition of Kevin Foust on June 30, 2023 filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 06/08/2023) (3) |
| Jun 7, 2023 | 205 | NOTICE OF SERVICE of Subpoena for Deposition Testimony Directed to Third Party Marco A. Passini filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 06/07/2023) (6) |
| Jun 7, 2023 | 206 | NOTICE OF SERVICE of Subpoena for Deposition Testimony Directed to Third Party Peter H. Smith filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 06/07/2023) (22) |
| Jun 7, 2023 | 207 | NOTICE OF SERVICE of Subpoena for Deposition Testimony Directed to Third Party Shangzhen Zhou filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 06/07/2023) (22) |
| Jun 7, 2023 | 208 | NOTICE OF SERVICE of Subpoena for Deposition Testimony Directed to Third Party Tannie Le filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 06/07/2023) (22) |
| Jun 7, 2023 | 209 | NOTICE OF SERVICE of Subpoena for Deposition Testimony Directed to Third Party Jurg M. Sommer filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 06/07/2023) (22) |
| Jun 7, 2023 | 210 | NOTICE to Take Deposition of Justin Huddleson on June 30, 2023 filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 06/07/2023) (3) |
| Jun 7, 2023 | 211 | NOTICE OF SERVICE of (1) Defendants' Responses and Objections to Plaintiffs' First Set of Requests for Admissions (Nos. 1-50), (2) Defendants' Responses and Objections to Plaintiffs' Third Set of Interrogatories (Nos. 14-23), and (3) Defendants' Responses and Objections to Plaintiffs' Fourth Set of Requests for Production of Documents and Things (Nos. 146-181) filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 06/07/2023) (4) |
| Jun 6, 2023 | 199 | NOTICE OF SERVICE of Subpoena directed to Kevin Foust filed by Aventis Inc., Genzyme Corporation.(Czerwonka, Scott) (Entered: 06/06/2023) (4) |
| Jun 6, 2023 | 200 | MOTION for Pro Hac Vice Appearance of Attorney Daniel Roberts - filed by Aventis Inc., Genzyme Corporation. (Wilks, David) (Entered: 06/06/2023) (2) |
| Jun 6, 2023 | 201 | MOTION for Pro Hac Vice Appearance of Attorney Judah Bellin - filed by Aventis Inc., Genzyme Corporation. (Wilks, David) (Entered: 06/06/2023) (2) |
| Jun 6, 2023 | 202 | MOTION for Pro Hac Vice Appearance of Attorney Brian Goldberg - filed by Aventis Inc., Genzyme Corporation. (Wilks, David) (Entered: 06/06/2023) (2) |
| Jun 6, 2023 | 203 | MOTION for Pro Hac Vice Appearance of Attorney Shyam Shanker - filed by Aventis Inc., Genzyme Corporation. (Wilks, David) (Entered: 06/06/2023) (2) |
| Jun 6, 2023 | 204 | MOTION for Pro Hac Vice Appearance of Attorney Pejmon Pashai - filed by Aventis Inc., Genzyme Corporation. (Wilks, David) (Entered: 06/06/2023) (2) |
| May 31, 2023 | 197 | NOTICE OF SERVICE of Subpoenas directed to Kevin Foust, James LItalien, and Ramesh Arjunji filed by Aventis Inc., Genzyme Corporation.(Czerwonka, Scott) (Entered: 05/31/2023) (4) |
| May 31, 2023 | 198 | NOTICE OF SERVICE of Plaintiffs' Fourth Set of Interrogatories filed by Aventis Inc., Genzyme Corporation.(Czerwonka, Scott) (Entered: 05/31/2023) (4) |
| May 30, 2023 | 196 | NOTICE OF SERVICE of Defendant's First Set of Requests for Admissions (Nos. 1-50) filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation.(Silver, Daniel) (Entered: 05/30/2023) (4) |
| May 26, 2023 | 195 | NOTICE to Take Deposition of Guang Qu on June 20, 2023 filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 05/26/2023) (3) |
| May 25, 2023 | 193 | NOTICE OF SERVICE of Defendants' Responses and Objections to Plaintiffs' Rule 30(b)(6) Notice of Deposition to Defendants filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 05/25/2023) (4) |
| May 25, 2023 | 194 | NOTICE OF SERVICE of Plaintiffs' Objections and Responses to Defendants' Notice of Deposition Pursuant to Rule 30(b)(6) filed by Aventis Inc., Genzyme Corporation.(Czerwonka, Scott) (Entered: 05/25/2023) (4) |
| May 23, 2023 | 192 | NOTICE OF SERVICE of Defendants' Fifth Set of Interrogatories to Plaintiffs filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 05/23/2023) (4) |
| May 19, 2023 | 184 | NOTICE to Take Deposition of Adria Tyndall on to be determined before June 30, 2023 filed by Aventis Inc., Genzyme Corporation.(Czerwonka, Scott) (Entered: 05/19/2023) (3) |
| May 19, 2023 | 185 | NOTICE to Take Deposition of Brandee Paknis on to be determined before June 30, 2023 filed by Aventis Inc., Genzyme Corporation.(Czerwonka, Scott) (Entered: 05/19/2023) (3) |
| May 19, 2023 | 186 | NOTICE to Take Deposition of Faith Ozsolak on to be determined before June 30, 2023 filed by Aventis Inc., Genzyme Corporation.(Czerwonka, Scott) (Entered: 05/19/2023) (3) |
| May 19, 2023 | 187 | NOTICE to Take Deposition of Katie Picone Powers on to be determined before June 30, 2023 filed by Aventis Inc., Genzyme Corporation.(Czerwonka, Scott) (Entered: 05/19/2023) (3) |
| May 19, 2023 | 188 | NOTICE to Take Deposition of Marshall DeChambre on to be determined before June 30, 2023 filed by Aventis Inc., Genzyme Corporation.(Czerwonka, Scott) (Entered: 05/19/2023) (3) |
| May 19, 2023 | 189 | NOTICE to Take Deposition of Patrick McOmber on to be determined before June 30, 2023 filed by Aventis Inc., Genzyme Corporation.(Czerwonka, Scott) (Entered: 05/19/2023) (3) |
| May 19, 2023 | 190 | NOTICE to Take Deposition of Tay Salimullah on to be determined before June 30, 2023 filed by Aventis Inc., Genzyme Corporation.(Czerwonka, Scott) (Entered: 05/19/2023) (3) |
| May 19, 2023 | 191 | NOTICE to Take Deposition of Robert Gleeson on to be determined before June 30, 2023 filed by Aventis Inc., Genzyme Corporation.(Czerwonka, Scott) (Entered: 05/19/2023) (3) |
| May 16, 2023 | 180 | NOTICE to Take Deposition of Barrie J. Carter on June 22, 2023 filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation.(Silver, Daniel) (Entered: 05/16/2023) (3) |
| May 16, 2023 | 181 | NOTICE to Take Deposition of Catherine O'Riordan on June 29, 2023 filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation.(Silver, Daniel) (Entered: 05/16/2023) (3) |
| May 16, 2023 | 182 | NOTICE to Take Deposition of Samuel Wadsworth on June 15, 2023 filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation.(Silver, Daniel) (Entered: 05/16/2023) (3) |
| May 16, 2023 | 183 | NOTICE to Take Deposition of John Fraser Wright on June 13, 2023 filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation.(Silver, Daniel) (Entered: 05/16/2023) (3) |
| May 9, 2023 | 179 | MOTION for Pro Hac Vice Appearance of Attorney George Lombardi and Ivan Poullaos - filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation. (Silver, Daniel) (Entered: 05/09/2023) (4) |
| May 8, 2023 | 178 | NOTICE OF SERVICE of (1) Plaintiffs First Set of Requests for Admission; (2) Plaintiffs Third Set of Interrogatories; and (3) Plaintiffs Fourth Set of Requests for Production of Documents and Things filed by Aventis Inc., Genzyme Corporation.(Czerwonka, Scott) (Entered: 05/08/2023) (3) |
| May 7, 2023 | 177 | Official Transcript of Markman Hearing held on 4/13/23 before Judge Richard G. Andrews. Court Reporter Heather M. Triozzi,Email: Heather_Triozzi@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 5/30/2023. Redacted Transcript Deadline set for 6/7/2023. Release of Transcript Restriction set for 8/7/2023. (Triozzi, Heather) (Entered: 05/07/2023) (141) |
| May 5, 2023 | 174 | NOTICE OF SERVICE of Defendants Second Supplemental Rule 26(a)(1)(A) Disclosures filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 05/05/2023) (3) |
| May 5, 2023 | 175 | STIPULATION and [Proposed] Order Regarding the Filing of Further Litigation by Aventis Inc., Genzyme Corporation. (Wilks, David) (Entered: 05/05/2023) (5) |
| May 5, 2023 | 176 | SO ORDERED Granting 175 STIPULATION and Proposed Order Regarding the Filing of Further Litigation. Signed by Judge Richard G. Andrews on 5/5/2023. (nms) (Entered: 05/05/2023) (5) |
| May 1, 2023 | 171 | MOTION for Pro Hac Vice Appearance of Attorney Sharon K. Gagliardi - filed by Aventis Inc., Genzyme Corporation. (Wilks, David) (Entered: 05/01/2023) (2) |
| May 1, 2023 | 172 | MOTION for Pro Hac Vice Appearance of Attorney Noah M. Leibowitz - filed by Aventis Inc., Genzyme Corporation. (Wilks, David) (Entered: 05/01/2023) (2) |
| May 1, 2023 | 173 | [SEALED] NOTICE to Take Deposition of Rule 30(b)6) Deposition of Plaintiffs Genzyme Corporation and Aventis Inc. on May 30, 2023 filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation. (Attachments: # 1 Certificate of Service)(Joyce, Alexandra) (Entered: 05/01/2023) (0) |
| Apr 26, 2023 | 167 | MOTION for Pro Hac Vice Appearance of Attorney Amanda K. Antons - filed by Aventis Inc., Genzyme Corporation. (Wilks, David) (Entered: 04/26/2023) (2) |
| Apr 26, 2023 | 168 | MOTION for Pro Hac Vice Appearance of Attorney Jonathan D.J. Loeb - filed by Aventis Inc., Genzyme Corporation. (Wilks, David) (Entered: 04/26/2023) (2) |
| Apr 26, 2023 | 169 | MOTION for Pro Hac Vice Appearance of Attorney Katherine A. Helm - filed by Aventis Inc., Genzyme Corporation. (Wilks, David) (Entered: 04/26/2023) (2) |
| Apr 26, 2023 | 170 | MOTION for Pro Hac Vice Appearance of Attorney Martin J. Black - filed by Aventis Inc., Genzyme Corporation. (Wilks, David) (Entered: 04/26/2023) (2) |
| Apr 25, 2023 | 166 | ORAL ORDER: I reviewed two letters. (D.I. 164 & 165 ). Novartis offers no reason for why it could just submit more legal arguments in a letter following a Markman hearing. The time to make the arguments was at the Markman hearing. If Novartis was blindsided by Genzymes arguments, Novartis should have said so at the hearing. The letter (D.I. 164 ) is STRUCK. Ordered by Judge Richard G. Andrews on 4/25/2023. (lah) (Entered: 04/25/2023) (0) |
| Apr 21, 2023 | 165 | Letter to the Honorable Richard G. Andrews, from David E. Wilks, regarding Defendants' letter dated April 20, 2023 (D.I. 164 ). (Wilks, David) Modified on 4/21/2023 (nms). (Entered: 04/21/2023) (2) |
| Apr 20, 2023 | 164 | Letter to The Honorable Richard G. Andrews from Daniel M. Silver regarding Claim Construction. (Attachments: # 1 Exhibits A-B)(Silver, Daniel) (Entered: 04/20/2023) (0) |
| Apr 13, 2023 | 163 | REDACTED VERSION of 162 Notice to Take Deposition, by Aventis Inc., Genzyme Corporation. (Attachments: # 1 Exhibit A)(Czerwonka, Scott) (Entered: 04/13/2023) (0) |
| Apr 6, 2023 | 162 | [SEALED] NOTICE to Take Deposition of Defendants Novartis Gene Therapies, Inc. and Novartis Pharmaceuticals Corporation on May 22, 2023 filed by Aventis Inc., Genzyme Corporation. (Attachments: # 1 Exhibit A, # 2 Certificate of Service)(Czerwonka, Scott) (Entered: 04/06/2023) (0) |
| Mar 31, 2023 | 161 | NOTICE OF SERVICE of Defendants' Supplemental Rule 26(a)(1)(A) filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation.(Silver, Daniel) (Entered: 03/31/2023) (3) |
| Mar 24, 2023 | 159 | REDACTED VERSION of 142 Reply Brief, by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibits A-C, # 2 Exhibit C part 2, # 3 Exhibit C part 3, # 4 Exhibits D-I)(Silver, Daniel) Modified on 3/24/2023 (nms). (Entered: 03/24/2023) (0) |
| Mar 24, 2023 | 160 | NOTICE OF SERVICE of Plaintiffs Objections and Second Supplemental Responses to Defendants First Set of Interrogatories (Nos. 1-13) filed by Aventis Inc., Genzyme Corporation.(Czerwonka, Scott) (Entered: 03/24/2023) (3) |
| Mar 17, 2023 | 158 | ORAL ORDER: The redacted filing (D.I. 156 ) is REJECTED because parts of it are redacted in its entirety. Absent a compelling reason, supported by a statement under oath by a party, redactions in their entirety are impermissible; redactions must be done so as to redact the least possible amount of the materials submitted. Failure to make a good faith attempt at such redactions may result in sanctions, the most common of which would be simply unsealing the entire filing. Redacting in its entirety a document that contains publicly available materials is prima facie evidence of bad faith. A revised redacted filings is DUE within five business days. Ordered by Judge Richard G. Andrews on 3/17/2023. (nms) (Entered: 03/17/2023) (0) |
| Mar 15, 2023 | 156 | REDACTED VERSION of 142 Reply Brief, by Aventis Inc., Genzyme Corporation. (Attachments: # 1 Exhibits A-B, # 2 Exhibit C, # 3 Exhibits D-I)(Czerwonka, Scott) Modified on 3/15/2023 (nms). (Entered: 03/15/2023) (0) |
| Mar 15, 2023 | 157 | NOTICE of Petitions for Inter Partes Review of a Patent-In-Suit Before the PTAB, by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit A, # 2 Exhibit B)(Joyce, Alexandra) Modified on 3/16/2023 (nms). (Entered: 03/15/2023) (0) |
| Mar 13, 2023 | 155 | ORAL ORDER: A Markman Hearing is now set for 4/13/2023, at 9:00 AM in Courtroom 6A. Ordered by Judge Richard G. Andrews on 3/13/2023. (nms) (Entered: 03/13/2023) (0) |
| Mar 9, 2023 | 154 | NOTICE OF SERVICE of (1) Plaintiffs Objections and Responses to Defendants Third Set of Requests for Production of Documents and Things (Nos. 54-75); (2) Plaintiffs Objections and Responses to Defendants Fourth Set of Interrogatories (Nos. 17-19) filed by Aventis Inc., Genzyme Corporation.(Czerwonka, Scott) (Entered: 03/09/2023) (2) |
| Mar 8, 2023 | 152 | STIPULATION and Proposed Order to Extend Time to submit a public redacted version of D.I. 142 to March 15, 2023 - filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 3/8/2023 (nms). (Entered: 03/08/2023) (2) |
| Mar 8, 2023 | 153 | SO ORDERED, re 152 STIPULATION and Proposed Order to Extend Time to submit a public redacted version of D.I. 142 to March 15, 2023. Signed by Judge Richard G. Andrews on 3/8/2023. (nms) (Entered: 03/08/2023) (0) |
| Mar 7, 2023 | 148 | STIPULATION and [Proposed] Order to Amend Case Schedule by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation. (Silver, Daniel) (Entered: 03/07/2023) (4) |
| Mar 7, 2023 | 149 | ORAL ORDER: In light of advisement from the parties that they have reached an agreement on the proposed schedule, and the Court being satisfied with the proposal, the discovery conference scheduled for 3/7/2023, is now CANCELED. Ordered by Judge Richard G. Andrews on 3/7/2023. (nms) (Entered: 03/07/2023) (0) |
| Mar 7, 2023 | 150 | ORAL ORDER: The Stipulation and Proposed Order Permitting Leave to File a Sur-Reply Brief (D.I. 145 ) is DISMISSED as moot (see D.I. 148 ). Ordered by Judge Richard G. Andrews on 3/7/2023. (nms) (Entered: 03/07/2023) (0) |
| Mar 7, 2023 | 151 | SO ORDERED Granting 148 Stipulation and Proposed Order to Amend Case Schedule (*Reset Deadlines: Fact Discovery completed by 6/30/2023; Dispositive Motions due by 11/10/2023) (see Order for further details). Signed by Judge Richard G. Andrews on 3/7/2023. (nms) (Entered: 03/07/2023) (4) |
| Mar 6, 2023 | 145 | STIPULATION and [Proposed] Order Permitting Defendants Leave to File a Sur-Reply In Further Opposition to Plaintiffs' Motion for Leave to File a Second Amended Complaint by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit A)(Silver, Daniel) (Entered: 03/06/2023) (0) |
| Mar 6, 2023 | 146 | REDACTED VERSION of 137 Answering Brief in Opposition, by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation. (Attachments: # 1 Part 2)(Silver, Daniel) Modified on 3/7/2023 (nms). (Entered: 03/06/2023) (0) |
| Mar 6, 2023 | 147 | ORAL ORDER: The motion for leave to file the second amended complaint (D.I. 119 ) is DENIED. It is too late to add a seventh patent with eight asserted claims to a complex case that already has two other asserted patent families with about 60 specified asserted claims. I am not persuaded that it is fair to Defendants to add a new patent that has not been the subject of discovery, and, in any event, I expect adding it would cause substantial delay (beyond what might or might not be required in the scheduling dispute set for tomorrow). There is no prejudice to Plaintiffs, as they can surely bring a suit based on the 288 patent whenever they want to do so. I also note Plaintiffs allegations in paragraphs 124-126, occupying nearly three pages of the proposed amended pleading, which (if I allowed them as a part of the trial) would likely lead to requests for additional expert witnesses on litigation practices, require decisions about which outside counsel to disqualify, and generally present significant trial management problems. Ordered by Judge Richard G. Andrews on 3/6/2023. (nms) (Entered: 03/06/2023) (0) |
| Mar 3, 2023 | 144 | REDACTED VERSION of 138 Letter, by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 3/3/2023 (nms). (Entered: 03/03/2023) (30) |
| Mar 1, 2023 | 142 | [SEALED] Reply Brief re 119 MOTION for Leave to File Second Amended Complaint, filed by Aventis Inc., Genzyme Corporation. (Attachments: # 1 Exhibits A-B, # 2 Exhibit C, # 3 Exhibits D-I, # 4 Certificate of Service)(Wilks, David) (Attachment 1 replaced on 3/3/2023) (nms). (Attachment 2 replaced on 3/3/2023) (nms). (Attachment 3 replaced on 3/3/2023) (nms). Modified on 3/3/2023 (nms). (Entered: 03/01/2023) (0) |
| Mar 1, 2023 | 143 | NOTICE OF SERVICE of (1) Plaintiffs Objections and Supplemental Responses to Defendants First Set of Interrogatories (Nos. 1-13); (2) Plaintiffs Objections and Supplemental Responses to Defendants Second Set of Interrogatories (Nos. 14-15); (3) Plaintiffs Objections and Supplemental Responses to Defendants Third Set of Interrogatories (No. 16) filed by Aventis Inc., Genzyme Corporation.(Czerwonka, Scott) (Entered: 03/01/2023) (2) |
| Feb 28, 2023 | 139 | STIPULATION and Proposed Order to Extend Time to submit a public redacted version of D.I. 137 to March 8, 2023 - filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 2/28/2023 (nms). (Entered: 02/28/2023) (2) |
| Feb 28, 2023 | 140 | Letter to the Honorable Richard G. Andrews, from David E. Wilks, regarding response to Defendants' request to amend the case schedule (D.I. 138 ). (Attachments: # 1 Proposed Order, # 2 Exhibits 1-6)(Wilks, David) Modified on 2/28/2023 (nms). (Entered: 02/28/2023) (0) |
| Feb 28, 2023 | 141 | NOTICE OF SERVICE of Plaintiffs First Amended Claim Charts Pursuant to Paragraph 4(c) of the Delaware Default Standard for Discovery filed by Aventis Inc., Genzyme Corporation.(Wilks, David) (Entered: 02/28/2023) (2) |
| Feb 24, 2023 | 138 | [SEALED] Letter to The Honorable Richard G. Andrews from Daniel M. Silver regarding Request to Amend the Case Schedule. (Attachments: # 1 Exhibits 1-12, # 2 Proposed Order, # 3 Certificate of Service)(Silver, Daniel) (Entered: 02/24/2023) (0) |
| Feb 22, 2023 | 135 | MOTION for Pro Hac Vice Appearance of Attorney Ashley Hatzenbihler - filed by Aventis Inc., Genzyme Corporation. (Wilks, David) (Entered: 02/22/2023) (4) |
| Feb 22, 2023 | 136 | ORAL ORDER: The parties have advised that a dispute has arisen requiring attention. The Court will hold a conference on 3/7/2023, at 10:00 AM in Courtroom 6A. In preparation for this conference the parties shall follow the Discovery Matters and Disputes procedure as set forth in the Scheduling Order. Further, both sides are requested to attach proposed orders with their letters. Ordered by Judge Richard G. Andrews on 2/22/2023. (nms) (Entered: 02/22/2023) (0) |
| Feb 22, 2023 | 137 | [SEALED] ANSWERING BRIEF in Opposition re 119 MOTION for Leave to File Second Amended Complaint filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation.Reply Brief due date per Local Rules is 3/1/2023. (Attachments: # 1 Exhibits A-H, # 2 Exhibits I-L, # 3 Certificate of Service)(Silver, Daniel) (Entered: 02/22/2023) (0) |
| Feb 21, 2023 | 133 | PROPOSED Order Granting Motion to Dismiss (D.I. 48 ), by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 2/21/2023 (nms). (Entered: 02/21/2023) (1) |
| Feb 21, 2023 | 134 | ORDER Granting 48 MOTION to Dismiss (*Party Novartis AG terminated). Signed by Judge Richard G. Andrews on 2/21/2023. (nms) (Entered: 02/21/2023) (1) |
| Feb 17, 2023 | 132 | NOTICE requesting Clerk to remove Oulu (Lulu) Wang, Ph.D. as co-counsel.. (Silver, Daniel) (Entered: 02/17/2023) (2) |
| Feb 16, 2023 | 131 | REDACTED VERSION of 123 Notice of Service of Subpoena, by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 2/16/2023 (nms). (Entered: 02/16/2023) (20) |
| Feb 14, 2023 | 128 | REDACTED VERSION of 120 Sealed Exhibits, by Aventis Inc., Genzyme Corporation. (Attachments: # 1 Exhibit 2)(Wilks, David) Modified on 2/14/2023 (nms). (Entered: 02/14/2023) (0) |
| Feb 14, 2023 | 129 | REDACTED VERSION of 121 Opening Brief in Support, by Aventis Inc., Genzyme Corporation. (Attachments: # 1 Exhibits 2-12)(Wilks, David) Modified on 2/14/2023 (nms). (Entered: 02/14/2023) (0) |
| Feb 14, 2023 | 130 | ORAL ORDER: The Joint Claim Construction Brief (D.I. 101 ) is UNSEALED. The sealed portions (pp. 63-65, 79-80) disclose nothing that will harm Plaintiffs. While it is doubtful that Exhibits 26 and 27 to D.I. 107 should be under seal, the Exhibits were not filed by the party seeking to seal them, the only arguably relevant portion is now unsealed, and the remainder is irrelevant. In light of the above, Exhibits 26 and 27 will remain under seal. Signed by Judge Richard G. Andrews on 2/14/2023. (nms) (Entered: 02/14/2023) (0) |
| Feb 13, 2023 | 125 | ORAL ORDER: In connection with a request to entirely seal two exhibits (consisting of 2001 entries in a lab notebook and a power point from 2005) to a joint claim construction brief, Plaintiffs submit a declaration from a lawyer. (D.I. 124). Defendants apparently are the ones who thought extrinsic confidential evidence was relevant to claim construction. No one identifies where the evidence is cited in the brief. In order to assist with my determination, Defendants are ordered to identify for me the pages of the brief that cite this evidence. Ordered by Judge Richard G. Andrews on 2/13/2023. (nms) (Entered: 02/13/2023) (0) |
| Feb 13, 2023 | 126 | Letter to The Honorable Richard G. Andrews, from Daniel M. Silver, regarding response to Oral Order (D.I. 125 ). (Silver, Daniel) Modified on 2/13/2023 (nms). (Entered: 02/13/2023) (1) |
| Feb 13, 2023 | 127 | MEMORANDUM OPINION: The Motion to Dismiss under Federal Rule of Civil Procedure 12(b)(2) for lack of personal jurisdiction (D.I. 48 ) is GRANTED. Within five days the parties shall submit a proposed order consistent with this Memorandum Opinion. Signed by Judge Richard G. Andrews on 2/13/2023. (nms) (Entered: 02/13/2023) (12) |
| Feb 10, 2023 | 124 | DECLARATION of Joshua R. Rich re 107 Appendix, Volume III of III, by Aventis Inc., Genzyme Corporation. (Czerwonka, Scott) Modified on 2/13/2023 (nms). (Entered: 02/10/2023) (3) |
| Feb 9, 2023 | 122 | NOTICE OF SERVICE of Subpoena directed to MediciNova, Inc. filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 02/09/2023) (18) |
| Feb 9, 2023 | 123 | [SEALED] NOTICE OF SERVICE of Subpoena directed to Armata Pharmaceuticals, Inc. filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation. (Attachments: # 1 Certificate of Service)(Joyce, Alexandra) (Entered: 02/09/2023) (0) |
| Feb 8, 2023 | 119 | MOTION for Leave to File Second Amended Complaint - filed by Aventis Inc., Genzyme Corporation. (Attachments: # 1 Proposed Order, # 2 7.1.1 Certification, # 3 Certificate of Service)(Wilks, David) Modified on 2/9/2023 (nms). (Entered: 02/08/2023) (0) |
| Feb 8, 2023 | 120 | [SEALED] EXHIBITS to 119 MOTION for Leave to File Second Amended Complaint, by Aventis Inc., Genzyme Corporation. (Attachments: # 1 Exhibit 2, # 2 Certificate of Service)(Wilks, David) Modified on 2/9/2023 (nms). (Entered: 02/08/2023) (0) |
| Feb 8, 2023 | 121 | [SEALED] OPENING BRIEF in Support re 119 MOTION for Leave to File Second Amended Complaint, filed by Aventis Inc., Genzyme Corporation. Answering Brief/Response due date per Local Rules is 2/22/2023. (Attachments: # 1 Exhibits 2-12, # 2 Certificate of Service)(Wilks, David) Modified on 2/9/2023 (nms). (Attachment 1 replaced on 2/9/2023) (nms). Modified on 2/9/2023 (nms). (Entered: 02/08/2023) (0) |
| Feb 7, 2023 | 117 | NOTICE OF SERVICE of Subpoena directed to Samuel Wadsworth filed by Novartis AG, Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 02/07/2023) (20) |
| Feb 7, 2023 | 118 | NOTICE OF SERVICE of (1) Novartis Gene Therapies, Inc. and Novartis Pharmaceuticals Corporations Third Set of Requests for Production of Documents and Things (Nos. 54-75) and (2) Novartis Gene Therapies, Inc. and Novartis Pharmaceuticals Corporations Fourth Set of Interrogatories to Plaintiffs (Nos. 17-19) filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 02/07/2023) (3) |
| Feb 6, 2023 | 116 | ORAL ORDER: The redacted filing (D.I. 115 ) is REJECTED because parts of it are redacted in its entirety. Absent a compelling reason, supported by a statement under oath by a party, redactions in their entirety are impermissible; redactions must be done so as to redact the least possible amount of the materials submitted. Failure to make a good faith attempt at such redactions may result in sanctions, the most common of which would be simply unsealing the entire filing. Redacting in its entirety a document that contains publicly available materials is prima facie evidence of bad faith. A revised redacted filings is DUE within five business days. Ordered by Judge Richard G. Andrews on 2/6/2023. (nms) (Entered: 02/06/2023) (0) |
| Feb 3, 2023 | 113 | Letter to The Honorable Richard G. Andrews, from Daniel M. Silver, regarding response to Plaintiffs' February 2, 2023, letter (D.I. 112 ). (Silver, Daniel) Modified on 2/3/2023 (nms). (Entered: 02/03/2023) (1) |
| Feb 3, 2023 | 114 | ORAL ORDER: The Markman hearing scheduled for 2/8/2023, is CANCELED, and will be rescheduled in due course. Ordered by Judge Richard G. Andrews on 2/3/2023. (nms) (Entered: 02/03/2023) (0) |
| Feb 3, 2023 | 115 | REDACTED VERSION of 107 Appendix, by Aventis Inc., Genzyme Corporation. (Czerwonka, Scott) (Entered: 02/03/2023) (5) |
| Feb 2, 2023 | 112 | Letter to the Honorable Richard G. Andrews, from David E. Wilks, regarding a recent development and to ask whether the Court would like to proceed with the Markman hearing scheduled for February 8, 2023. (Wilks, David) Modified on 2/2/2023 (nms). (Entered: 02/02/2023) (2) |
| Jan 31, 2023 | 111 | NOTICE of Appearance by Donald C. Vavala, III on behalf of Aventis Inc., Genzyme Corporation (Vavala, Donald) (Entered: 01/31/2023) (2) |
| Jan 30, 2023 | 110 | MOTION for Pro Hac Vice Appearance of Attorney Emily R. Gabranski and Marta Garcia Daneshvar - filed by Novartis AG, Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 01/30/2023) (4) |
| Jan 24, 2023 | 108 | APPENDIX, Volume I of III re 101 Joint Claim Construction Brief, by Aventis Inc., Genzyme Corporation. (Czerwonka, Scott) Modified on 1/24/2023 (nms). (Entered: 01/24/2023) (30) |
| Jan 24, 2023 | 109 | APPENDIX, Volume II of III re 101 Joint Claim Construction Brief, by Aventis Inc., Genzyme Corporation. (Czerwonka, Scott) Modified on 1/24/2023 (nms). (Entered: 01/24/2023) (30) |
| Jan 23, 2023 | 107 | [SEALED] APPENDIX, Volume III of III to 101 Joint Claim Construction Brief, by Aventis Inc., Genzyme Corporation. (Attachments: # 1 Certificate of Service)(Czerwonka, Scott) Modified on 1/23/2023 (nms). (Main Document 107 replaced on 1/24/2023) (nms). Modified on 1/24/2023 (nms). (Entered: 01/23/2023) (0) |
| Jan 20, 2023 | 105 | REDACTED VERSION of 101 Joint Claim Construction Brief, by Aventis Inc., Genzyme Corporation. (Czerwonka, Scott) (Entered: 01/20/2023) (30) |
| Jan 17, 2023 | 104 | SO ORDERED as amended re 103 Joint Motion Rrequesting Claim Construction Hearing. Signed by Judge Richard G. Andrews on 1/17/2023. (nms) (Entered: 01/17/2023) (4) |
| Jan 13, 2023 | 101 | Joint Claim Construction Brief, filed by Aventis Inc., Genzyme Corporation. (Attachments: # 2 Certificate of Service)(Wilks, David) Modified on 1/17/2023 (nms). (Main Document 101 replaced on 1/17/2023) (nms). (Main Document 101 replaced on 1/18/2023) (nms). Modified on 2/14/2023 (nms). (Entered: 01/13/2023) (0) |
| Jan 13, 2023 | 103 | Joint Motion requesting Claim Construction Hearing - filed by Aventis Inc., Genzyme Corporation. (Wilks, David) Modified on 1/17/2023 (nms). (Entered: 01/13/2023) (4) |
| Jan 5, 2023 | 99 | Amended Stipulated Protective Order, by Aventis Inc., Genzyme Corporation. (Attachments: # 1 Exhibit A)(Czerwonka, Scott) Modified on 1/5/2023 (nms). (Entered: 01/05/2023) (0) |
| Jan 5, 2023 | 100 | SO ORDERED Granting 99 Amended Stipulated Protective Order. Signed by Judge Richard G. Andrews on 1/5/2023. (nms) (Entered: 01/05/2023) (30) |
| Dec 29, 2022 | 98 | NOTICE OF SERVICE of Defendants' Sur-reply Claim Construction Brief filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation.(Silver, Daniel) (Entered: 12/29/2022) (3) |
| Dec 27, 2022 | 97 | NOTICE OF SERVICE of Defendants' Objections and Responses to Plaintiff's Third Set of Requests for Production of Documents and Things (Nos. 118-145) filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation.(Silver, Daniel) (Entered: 12/27/2022) (3) |
| Dec 16, 2022 | 96 | REDACTED VERSION of 90 Exhibit to a Document, by Aventis Inc., Genzyme Corporation. (Czerwonka, Scott) (Entered: 12/16/2022) (30) |
| Dec 9, 2022 | 95 | STIPULATION TO EXTEND TIME to submit a public redacted version of D.I. 90 to December 16, 2022 - filed by Novartis AG, Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 12/09/2022) (3) |
| Dec 7, 2022 | 94 | NOTICE OF SERVICE of Plaintiffs' Reply Claim Construction Brief and Declaration of Gary Kurtzman, M.D. filed by Aventis Inc., Genzyme Corporation.(Czerwonka, Scott) (Entered: 12/07/2022) (2) |
| Dec 6, 2022 | 93 | ORAL ORDER: After consideration of the parties letters (D.I. 89 & 92 ) and related exhibits, the Court rules in favor of Genzyme. Defendants are to produce §§ 2.3 & 3.2 of the BLA on an Outside Counsel Eyes Only basis. The Court understands that there is no such designation in the protective order presently, and the parties will need to revise the protective order. In the meantime, the production should be made within five business days under the authority of D.Del. LR 26.2. The Court will consider further specific applications from Genzyme. Generally-speaking, the Court does not favor relevance redactions, even of highly proprietary information, because the net effect is to make what is produced incomprehensible, or nearly incomprehensible, and therefore useless. Ordered by Judge Richard G. Andrews on 12/6/2022. (nms) (Entered: 12/06/2022) (0) |
| Dec 1, 2022 | 92 | Letter to the Honorable Richard G. Andrdews from Daniel M. Silver regarding Discovery Disputes. (Attachments: # 1 Exhibits 1-6, # 2 Proposed Order)(Silver, Daniel) (Entered: 12/01/2022) (Main Document) (5) |
| Dec 1, 2022 | 92 | Letter to the Honorable Richard G. Andrdews from Daniel M. Silver regarding Discovery Disputes. (Attachments: # 1 Exhibits 1-6, # 2 Proposed Order)(Silver, Daniel) (Entered: 12/01/2022) (Exhibits 1-6) (30) |
| Dec 1, 2022 | 92 | Letter to the Honorable Richard G. Andrdews from Daniel M. Silver regarding Discovery Disputes. (Attachments: # 1 Exhibits 1-6, # 2 Proposed Order)(Silver, Daniel) (Entered: 12/01/2022) (Proposed Order) (2) |
| Nov 30, 2022 | 91 | MOTION for Pro Hac Vice Appearance of Attorney James C. Gumina - filed by Aventis Inc., Genzyme Corporation. (Czerwonka, Scott) (Entered: 11/30/2022) (3) |
| Nov 29, 2022 | 89 | Letter to The Honorable Richard G. Andrews from Scott B.Czerwonka regarding discovery dispute. (Attachments: # 1 Exhibit B, # 2 Exhibit C, # 3 Exhibit D, # 4 Exhibit E, # 5 Exhibit F, # 6 Exhibit G, # 7 Exhibit H, # 8 Text of Proposed Order)(Czerwonka, Scott) (Entered: 11/29/2022) (Main Document) (4) |
| Nov 29, 2022 | 90 | [SEALED] Exhibits to 89 Letter, by Aventis Inc., Genzyme Corporation. (Attachments: # 1 Exhibit A2, # 2 Exhibit A3, # 3 Exhibit A4, # 4 Exhibit A5, # 5 Exhibit A6, # 6 Exhibit A7, # 7 Certificate of Service)(Czerwonka, Scott) Modified on 11/29/2022 (nms). (Entered: 11/29/2022) (0) |
| Nov 29, 2022 | 89 | Letter to The Honorable Richard G. Andrews from Scott B.Czerwonka regarding discovery dispute. (Attachments: # 1 Exhibit B, # 2 Exhibit C, # 3 Exhibit D, # 4 Exhibit E, # 5 Exhibit F, # 6 Exhibit G, # 7 Exhibit H, # 8 Text of Proposed Order)(Czerwonka, Scott) (Entered: 11/29/2022) (Exhibit B) (12) |
| Nov 29, 2022 | 89 | Letter to The Honorable Richard G. Andrews from Scott B.Czerwonka regarding discovery dispute. (Attachments: # 1 Exhibit B, # 2 Exhibit C, # 3 Exhibit D, # 4 Exhibit E, # 5 Exhibit F, # 6 Exhibit G, # 7 Exhibit H, # 8 Text of Proposed Order)(Czerwonka, Scott) (Entered: 11/29/2022) (Exhibit C) (7) |
| Nov 29, 2022 | 89 | Letter to The Honorable Richard G. Andrews from Scott B.Czerwonka regarding discovery dispute. (Attachments: # 1 Exhibit B, # 2 Exhibit C, # 3 Exhibit D, # 4 Exhibit E, # 5 Exhibit F, # 6 Exhibit G, # 7 Exhibit H, # 8 Text of Proposed Order)(Czerwonka, Scott) (Entered: 11/29/2022) (Exhibit D) (10) |
| Nov 29, 2022 | 89 | Letter to The Honorable Richard G. Andrews from Scott B.Czerwonka regarding discovery dispute. (Attachments: # 1 Exhibit B, # 2 Exhibit C, # 3 Exhibit D, # 4 Exhibit E, # 5 Exhibit F, # 6 Exhibit G, # 7 Exhibit H, # 8 Text of Proposed Order)(Czerwonka, Scott) (Entered: 11/29/2022) (Exhibit E) (30) |
| Nov 29, 2022 | 89 | Letter to The Honorable Richard G. Andrews from Scott B.Czerwonka regarding discovery dispute. (Attachments: # 1 Exhibit B, # 2 Exhibit C, # 3 Exhibit D, # 4 Exhibit E, # 5 Exhibit F, # 6 Exhibit G, # 7 Exhibit H, # 8 Text of Proposed Order)(Czerwonka, Scott) (Entered: 11/29/2022) (Exhibit F) (4) |
| Nov 29, 2022 | 89 | Letter to The Honorable Richard G. Andrews from Scott B.Czerwonka regarding discovery dispute. (Attachments: # 1 Exhibit B, # 2 Exhibit C, # 3 Exhibit D, # 4 Exhibit E, # 5 Exhibit F, # 6 Exhibit G, # 7 Exhibit H, # 8 Text of Proposed Order)(Czerwonka, Scott) (Entered: 11/29/2022) (Exhibit G) (7) |
| Nov 29, 2022 | 89 | Letter to The Honorable Richard G. Andrews from Scott B.Czerwonka regarding discovery dispute. (Attachments: # 1 Exhibit B, # 2 Exhibit C, # 3 Exhibit D, # 4 Exhibit E, # 5 Exhibit F, # 6 Exhibit G, # 7 Exhibit H, # 8 Text of Proposed Order)(Czerwonka, Scott) (Entered: 11/29/2022) (Exhibit H) (15) |
| Nov 29, 2022 | 89 | Letter to The Honorable Richard G. Andrews from Scott B.Czerwonka regarding discovery dispute. (Attachments: # 1 Exhibit B, # 2 Exhibit C, # 3 Exhibit D, # 4 Exhibit E, # 5 Exhibit F, # 6 Exhibit G, # 7 Exhibit H, # 8 Text of Proposed Order)(Czerwonka, Scott) (Entered: 11/29/2022) (Text of Proposed Order) (1) |
| Nov 28, 2022 | 88 | NOTICE OF SERVICE of Plaintiffs Objections and Responses to Defendants Third Set of Interrogatories (No. 16) filed by Aventis Inc., Genzyme Corporation.(Czerwonka, Scott) (Entered: 11/28/2022) (2) |
| Nov 23, 2022 | 87 | NOTICE OF SERVICE of Plaintiffs' Third Set of Requests for the Production of Documents and Things Nos. 118-145 filed by Aventis Inc., Genzyme Corporation.(Wilks, David) (Entered: 11/23/2022) (2) |
| Nov 22, 2022 | 86 | ORAL ORDER: Dr. Kay is not immediately available for deposition for reasons beyond anyones control. That is good cause. Genzymes reply brief is due December 7, 2022. (D.I. 83 -3 at 11). Novartiss sur-reply brief is due December 29, 2022. (D.I. 84 at 8). The parties ought to agree on when the Joint Claim Construction Brief will be filed, bearing in mind that there is no rush in view of the Markman hearing being scheduled for February 8th. Ordered by Judge Richard G. Andrews on 11/22/2022. (nms) (Entered: 11/22/2022) (0) |
| Nov 21, 2022 | 84 | RESPONSE to 83 MOTION to Amend the Scheduling Order, filed by Novartis AG, Novartis Gene Therapies, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2)(Joyce, Alexandra) Modified on 11/21/2022 (nms). (Entered: 11/21/2022) (Main Document) (9) |
| Nov 21, 2022 | 85 | ORAL ORDER: The parties have advised that disputes have arisen requiring judicial attention. The Court will hold a discovery conference on 12/8/2022, at 9:00 AM in Courtroom 6A. In preparation for this conference the parties shall follow the Discovery Matters and Disputes procedure as set forth in the Scheduling Order. Ordered by Judge Richard G. Andrews on 11/21/2022. (nms) (Entered: 11/21/2022) (0) |
| Nov 21, 2022 | 84 | RESPONSE to 83 MOTION to Amend the Scheduling Order, filed by Novartis AG, Novartis Gene Therapies, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2)(Joyce, Alexandra) Modified on 11/21/2022 (nms). (Entered: 11/21/2022) (Exhibit 1) (14) |
| Nov 21, 2022 | 84 | RESPONSE to 83 MOTION to Amend the Scheduling Order, filed by Novartis AG, Novartis Gene Therapies, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2)(Joyce, Alexandra) Modified on 11/21/2022 (nms). (Entered: 11/21/2022) (Exhibit 2) (5) |
| Nov 18, 2022 | 83 | MOTION to Amend the Scheduling Order - filed by Aventis Inc., Genzyme Corporation. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Proposed Order)(Wilks, David) Modified on 11/18/2022 (nms). (Entered: 11/18/2022) (Main Document) (7) |
| Nov 18, 2022 | 83 | MOTION to Amend the Scheduling Order - filed by Aventis Inc., Genzyme Corporation. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Proposed Order)(Wilks, David) Modified on 11/18/2022 (nms). (Entered: 11/18/2022) (Exhibit A) (30) |
| Nov 18, 2022 | 83 | MOTION to Amend the Scheduling Order - filed by Aventis Inc., Genzyme Corporation. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Proposed Order)(Wilks, David) Modified on 11/18/2022 (nms). (Entered: 11/18/2022) (Exhibit B) (4) |
| Nov 18, 2022 | 83 | MOTION to Amend the Scheduling Order - filed by Aventis Inc., Genzyme Corporation. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Proposed Order)(Wilks, David) Modified on 11/18/2022 (nms). (Entered: 11/18/2022) (Text of Proposed Order) (12) |
| Nov 10, 2022 | 82 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Defendants' Answering Claim Constructin Brief and Declaration of Dr. Mark Kay, M.D., Ph.D. filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) |
| Oct 28, 2022 | 81 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Novartis Gene Therapies, Inc. and Novartis Pharmaceuticals Corporation's Third Set of Interrogatories to Plaintiffs (No. 16) filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) |
| Oct 12, 2022 | 80 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Plaintiffs' Opening Construction Brief filed by Aventis Inc., Genzyme Corporation.(Czerwonka, Scott) |
| Oct 11, 2022 | 78 | Claim Construction Chart (29) Docket Text: AMENDED Claim Construction Chart, by Aventis Inc., Genzyme Corporation. (Czerwonka, Scott) Modified on 10/11/2022 (nms). |
| Oct 11, 2022 | 79 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of (1) Defendants' First Amended Invalidity Contentions Regarding U.S. Patent Nos. 6,596,535, 7,125,717, 7,785,888, 7,846,729, 8,093,054, and 9,051,542, and (2) Defendants' First Supplemental Objections and Responses to Plaintiff's Interrogatories Nos. 1, 6-8, and 10-12 filed by Novartis AG, Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) |
| Sep 20, 2022 | 77 | Claim Construction Chart (Main Document) (30) Docket Text: JOINT Claim Construction Chart, by Aventis Inc., Genzyme Corporation. (Attachments: # (1) Exhibits A1 - A3, # (2) Exhibits A4 - A6, # (3) Exhibits B1 - B3, # (4) Exhibits B4 - B7, # (5) Exhibits B8 - B15, # (6) Exhibit C)(Wilks, David) Modified on 9/21/2022 (nms). |
| Sep 20, 2022 | 77 | Claim Construction Chart (Exhibit A1 - A3) (30) Docket Text: JOINT Claim Construction Chart, by Aventis Inc., Genzyme Corporation. (Attachments: # (1) Exhibits A1 - A3, # (2) Exhibits A4 - A6, # (3) Exhibits B1 - B3, # (4) Exhibits B4 - B7, # (5) Exhibits B8 - B15, # (6) Exhibit C)(Wilks, David) Modified on 9/21/2022 (nms). |
| Sep 20, 2022 | 77 | Claim Construction Chart (Exhibit A4 - A6) (30) Docket Text: JOINT Claim Construction Chart, by Aventis Inc., Genzyme Corporation. (Attachments: # (1) Exhibits A1 - A3, # (2) Exhibits A4 - A6, # (3) Exhibits B1 - B3, # (4) Exhibits B4 - B7, # (5) Exhibits B8 - B15, # (6) Exhibit C)(Wilks, David) Modified on 9/21/2022 (nms). |
| Sep 20, 2022 | 77 | Claim Construction Chart (Exhibit B1 - B3) (30) Docket Text: JOINT Claim Construction Chart, by Aventis Inc., Genzyme Corporation. (Attachments: # (1) Exhibits A1 - A3, # (2) Exhibits A4 - A6, # (3) Exhibits B1 - B3, # (4) Exhibits B4 - B7, # (5) Exhibits B8 - B15, # (6) Exhibit C)(Wilks, David) Modified on 9/21/2022 (nms). |
| Sep 20, 2022 | 77 | Claim Construction Chart (Exhibit B4 - B7) (30) Docket Text: JOINT Claim Construction Chart, by Aventis Inc., Genzyme Corporation. (Attachments: # (1) Exhibits A1 - A3, # (2) Exhibits A4 - A6, # (3) Exhibits B1 - B3, # (4) Exhibits B4 - B7, # (5) Exhibits B8 - B15, # (6) Exhibit C)(Wilks, David) Modified on 9/21/2022 (nms). |
| Sep 20, 2022 | 77 | Claim Construction Chart (Exhibit B8 - B15) (30) Docket Text: JOINT Claim Construction Chart, by Aventis Inc., Genzyme Corporation. (Attachments: # (1) Exhibits A1 - A3, # (2) Exhibits A4 - A6, # (3) Exhibits B1 - B3, # (4) Exhibits B4 - B7, # (5) Exhibits B8 - B15, # (6) Exhibit C)(Wilks, David) Modified on 9/21/2022 (nms). |
| Sep 20, 2022 | 77 | Claim Construction Chart (Exhibit C) (30) Docket Text: JOINT Claim Construction Chart, by Aventis Inc., Genzyme Corporation. (Attachments: # (1) Exhibits A1 - A3, # (2) Exhibits A4 - A6, # (3) Exhibits B1 - B3, # (4) Exhibits B4 - B7, # (5) Exhibits B8 - B15, # (6) Exhibit C)(Wilks, David) Modified on 9/21/2022 (nms). |
| Sep 15, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [76] STIPULATION and Proposed Order to Extend Time to file the Joint Claim Construction Chart to September 20, 2022. Signed by Judge Richard G. Andrews on 9/15/2022. (nms) |
| Sep 15, 2022 | 76 | Stipulation to EXTEND Time (3) Docket Text: STIPULATION TO EXTEND TIME to file the Joint Claim Construction Chart to September 20, 2022 - filed by Aventis Inc., Genzyme Corporation. (Wilks, David) |
| Sep 13, 2022 | 75 | Notice of Service (Main Document) (2) Docket Text: NOTICE OF SERVICE of Subpoenas filed by Novartis AG, Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation. (Attachments: # (1) Subpoena Directed to Barrie Carter, # (2) Subpoena Directed to Guang Qu, # (3) Subpoena Directed to John Wright)(Silver, Daniel) |
| Sep 13, 2022 | 75 | Notice of Service (Subpoena Directed to Barrie Carter) (19) Docket Text: NOTICE OF SERVICE of Subpoenas filed by Novartis AG, Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation. (Attachments: # (1) Subpoena Directed to Barrie Carter, # (2) Subpoena Directed to Guang Qu, # (3) Subpoena Directed to John Wright)(Silver, Daniel) |
| Sep 13, 2022 | 75 | Notice of Service (Subpoena Directed to Guang Qu) (19) Docket Text: NOTICE OF SERVICE of Subpoenas filed by Novartis AG, Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation. (Attachments: # (1) Subpoena Directed to Barrie Carter, # (2) Subpoena Directed to Guang Qu, # (3) Subpoena Directed to John Wright)(Silver, Daniel) |
| Sep 13, 2022 | 75 | Notice of Service (Subpoena Directed to John Wright) (19) Docket Text: NOTICE OF SERVICE of Subpoenas filed by Novartis AG, Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation. (Attachments: # (1) Subpoena Directed to Barrie Carter, # (2) Subpoena Directed to Guang Qu, # (3) Subpoena Directed to John Wright)(Silver, Daniel) |
| Sep 12, 2022 | 74 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Plaintiffs Objections and Responses to Defendants Second Set of Requests for Production of Documents and Things (Nos. 52-53) filed by Aventis Inc., Genzyme Corporation.(Wilks, David) |
| Sep 8, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [73] STIPULATION to Extend Time to submit Joint Claim Construction Chart to September 16, 2022. Signed by Judge Richard G. Andrews on 9/8/2022. (nms) |
| Sep 8, 2022 | 73 | Stipulation to EXTEND Time (3) Docket Text: STIPULATION TO EXTEND TIME to submit Joint Claim Construction Chart to September 16, 2022 - filed by Novartis AG, Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) |
| Aug 17, 2022 | 71 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Plaintiffs Identification of Claim Terms for Construction and Proposed Constructions filed by Aventis Inc., Genzyme Corporation.(Czerwonka, Scott) |
| Aug 17, 2022 | 72 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Defendants' Claim Construction Discloures filed by Novartis AG, Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Aug 15, 2022 | 70 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Plaintiffs' Objections and Responses to Defendants' Second Set of Interrogatories (Nos. 14-15) filed by Aventis Inc., Genzyme Corporation.(Czerwonka, Scott) |
| Aug 12, 2022 | 69 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of (1) Novartis Gene Therapies, Inc. and Novartis Pharmaceuticals Corporations Second Set of Requests for Production of Documents and Things (Nos. 52-53) and (2) Defendants Second Supplemental Objections and Responses to Plaintiffs First Set of Requests for Production of Documents and Things (Nos. 1-100) filed by Novartis AG, Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Aug 8, 2022 | 68 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of (1) Defendants' Objections and Responses to Plaintiffs' Second Set of Interrogatories (Nos. 10-13) and (2) Defendants' Objections and Responses to Plaintiffs' Second Set of Requests for Production of Documents and Things (Nos. 101-117) filed by Novartis AG, Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) |
| Jul 21, 2022 | 67 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Defendants' Initial Invalidity Contentions Regarding U.S. Patent Nos. 6,596,535, 7,125,717, 7,785,888, 7,846,729, 8,093,054, and 9,051,542 filed by Novartis AG, Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Jul 18, 2022 | 66 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Novartis Gene Therapies, Inc. and Novartis Pharmaceuticals Corporation's Second Set of Interrogatories to Plaintiffs (Nos. 14-15) filed by Novartis AG, Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Jul 7, 2022 | 65 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Plaintiffs' Second Set of Interrogatories and Plaintiffs' Second Set of Requests for Production of Documents and Things filed by Aventis Inc., Genzyme Corporation.(Wilks, David) |
| Jul 1, 2022 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney M. David Weingarten, PhD, Christopher Weber, PhD, and Oulu Wang, PhD for Novartis AG, Novartis Gene Therapies, Inc., and Novartis Pharmaceuticals Corporation added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) |
| Jul 1, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [64] MOTION for Pro Hac Vice Appearance of Attorney Margot M. Wilson, filed by Aventis Inc., Genzyme Corporation, [63] MOTION for Pro Hac Vice Appearance of Attorney James L. Lovsin, filed by Aventis Inc., Genzyme Corporation. Signed by Judge Richard G. Andrews on 7/1/2022. (nms) |
| Jul 1, 2022 | 63 | Motion for Leave to Appear Pro Hac Vice (3) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney James L. Lovsin - filed by Aventis Inc., Genzyme Corporation. (Wilks, David) |
| Jul 1, 2022 | 64 | Motion for Leave to Appear Pro Hac Vice (3) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Margot M. Wilson - filed by Aventis Inc., Genzyme Corporation. (Wilks, David) |
| Jun 30, 2022 | 62 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Defendants' Supplemental Objections And Responses To Plaintiffs' First Set Of Requests For Production Of Documents And Things (Nos. 1-100) filed by Novartis AG.(Silver, Daniel) |
| Jun 21, 2022 | 61 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Plaintiffs Initial Claim Charts Pursuant To Paragraph 4(c) of the Delaware Default Standard for Discovery filed by Aventis Inc., Genzyme Corporation.(Wilks, David) |
| Jun 20, 2022 | 60 | Reply Brief (15) Docket Text: REPLY BRIEF re [48] MOTION to Dismiss filed by Novartis AG. (Silver, Daniel) |
| Jun 8, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [59] STIPULATION and Proposed Order to Extend Time (*Reset Briefing Schedule: re [48] MOTION to Dismiss. Reply Brief due 6/20/2022). Signed by Judge Richard G. Andrews on 6/8/2022. (nms) |
| Jun 8, 2022 | 59 | Stipulation to EXTEND Time (2) Docket Text: STIPULATION and Proposed Order to Extend Time - filed by Novartis AG. (Silver, Daniel) Modified on 6/8/2022 (nms). |
| Jun 7, 2022 | N/A | CORRECTING ENTRY: (0) Docket Text: CORRECTING ENTRY: The discovery filed at D.I. 57 and D.I. 58 has been removed from the docket per the filer's request. The Notices of Service filed at D.I. 59 and D.I. 60 have also been removed per the filer's request as the filings contained errors. Amended notices of service will be refiled. (nms) |
| Jun 7, 2022 | 57 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Plaintiffs Objections and Responses to Defendants First Set of Requests for Production of Documents and Things (Nos. 1-15), filed by Aventis Inc., Genzyme Corporation.(Wilks, David) Modified on 6/7/2022 (nms). |
| Jun 7, 2022 | 58 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Objections and Responses to Defendants First Set of Interrogatories (Nos. 1-13), filed by Aventis Inc., Genzyme Corporation.(Wilks, David) Modified on 6/7/2022 (nms). |
| Jun 6, 2022 | 55 | Response to Motion (22) Docket Text: RESPONSE to[48] MOTION to Dismiss, filed by Aventis Inc., Genzyme Corporation. (Wilks, David) Modified on 6/6/2022 (nms). |
| Jun 6, 2022 | 56 | Declaration (Main Document) (4) Docket Text: DECLARATION re [55] Response, by Aventis Inc., Genzyme Corporation. (Attachments: # (1) Exhibit 1, # (2) Exhibits 2-9, # (3) Exhibits 10-17)(Wilks, David) Modified on 6/7/2022 (nms). |
| Jun 6, 2022 | 56 | Declaration (Exhibit Exhibit 1 to Declaration of Joshua R. Rich) (6) Docket Text: DECLARATION re [55] Response, by Aventis Inc., Genzyme Corporation. (Attachments: # (1) Exhibit 1, # (2) Exhibits 2-9, # (3) Exhibits 10-17)(Wilks, David) Modified on 6/7/2022 (nms). |
| Jun 6, 2022 | 56 | Declaration (Exhibit Exhibit 2-9 to Declaration of Joshua R. Rich) (30) Docket Text: DECLARATION re [55] Response, by Aventis Inc., Genzyme Corporation. (Attachments: # (1) Exhibit 1, # (2) Exhibits 2-9, # (3) Exhibits 10-17)(Wilks, David) Modified on 6/7/2022 (nms). |
| Jun 6, 2022 | 56 | Declaration (Exhibit Exhibits 10-17 to Declaration of Joshua R. Rich) (30) Docket Text: DECLARATION re [55] Response, by Aventis Inc., Genzyme Corporation. (Attachments: # (1) Exhibit 1, # (2) Exhibits 2-9, # (3) Exhibits 10-17)(Wilks, David) Modified on 6/7/2022 (nms). |
| Jun 3, 2022 | 54 | Notice Requesting Removal of Co-Counsel (2) Docket Text: NOTICE requesting Clerk to remove Michael Galgano as co-counsel.. (Joyce, Alexandra) |
| May 24, 2022 | 53 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Defendants' Production of Core Technical Documents Pursuant to Paragraph 4(b) of the Delaware Default Standard of Discovery filed by Novartis AG, Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) |
| May 23, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [47] MOTION for Pro Hac Vice Appearance of Attorney M. David Weingarten, Ph.D., Oulu (Lulu) Wang, Ph.D., and Christopher Weber, Ph.D., filed by Novartis AG, Novartis Pharmaceuticals Corporation, Novartis Gene Therapies, Inc.. Signed by Judge Richard G. Andrews on 5/23/2022. (nms) |
| May 23, 2022 | 47 | Motion for Leave to Appear Pro Hac Vice (5) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney M. David Weingarten, Ph.D., Oulu (Lulu) Wang, Ph.D., and Christopher Weber, Ph.D. - filed by Novartis AG, Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) |
| May 23, 2022 | 48 | Motion to Dismiss/Lack of Personal Jurisdiction (Main Document) (2) Docket Text: MOTION to Dismiss - filed by Novartis AG. (Attachments: # (1) Proposed Order)(Joyce, Alexandra) Modified on 5/23/2022 (nms). |
| May 23, 2022 | 48 | Motion to Dismiss/Lack of Personal Jurisdiction (Proposed Order) (1) Docket Text: MOTION to Dismiss - filed by Novartis AG. (Attachments: # (1) Proposed Order)(Joyce, Alexandra) Modified on 5/23/2022 (nms). |
| May 23, 2022 | 49 | Opening Brief in Support (20) Docket Text: OPENING BRIEF in Support re [48] MOTION to Dismiss, filed by Novartis AG.Answering Brief/Response due date per Local Rules is 6/6/2022. (Joyce, Alexandra) Modified on 5/23/2022 (nms). |
| May 23, 2022 | 50 | Declaration (3) Docket Text: DECLARATION re [49] Opening Brief in Support, by Novartis AG. (Joyce, Alexandra) Modified on 5/23/2022 (nms). |
| May 23, 2022 | 51 | Declaration (Main Document) (2) Docket Text: DECLARATION re [49] Opening Brief in Support, by Novartis AG. (Attachments: # (1) Exhibits A-B)(Joyce, Alexandra) Modified on 5/23/2022 (nms). |
| May 23, 2022 | 51 | Declaration (Exhibits A-B) (30) Docket Text: DECLARATION re [49] Opening Brief in Support, by Novartis AG. (Attachments: # (1) Exhibits A-B)(Joyce, Alexandra) Modified on 5/23/2022 (nms). |
| May 23, 2022 | 52 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of (1) Defendants' Objections and Responses to Plaintiffs' First Set of Interrogatories (Nos. 1-9), and (2) Defendants' Objections and Responses to Plaintiffs' First Set of Requests for Production of Documents and Things (Nos. 1-100) filed by Novartis AG, Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) |
| May 19, 2022 | 45 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Plaintiffs Paragraph 3 Disclosures under the Default Standard of Discovery filed by Aventis Inc., Genzyme Corporation.(Czerwonka, Scott) |
| May 19, 2022 | 46 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Novartis Gene Therapies, Inc. and Novartis Pharmaceuticals Corporation's Initial Disclosures Pursuant to Paragraph 3 of the Default Standard for Discovery of ESI filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) |
| May 16, 2022 | 44 | Order (26) Docket Text: SO ORDERED Granting [43] Stipulated Protective Order. Signed by Judge Richard G. Andrews on 5/16/2022. (nms) |
| May 13, 2022 | 42 | Order (8) Docket Text: SO ORDERED Granting [41] Joint Stipulated Terms for Production of Electronically Stored Information and Proposed Order. Signed by Judge Richard G. Andrews on 5/13/2022. (nms) |
| May 13, 2022 | 43 | Stipulation (Main Document) (23) Docket Text: STIPULATION Protective Order by Aventis Inc., Genzyme Corporation. (Attachments: # (1) Exhibit A)(Czerwonka, Scott) |
| May 13, 2022 | 43 | Stipulation (Exhibit A) (3) Docket Text: STIPULATION Protective Order by Aventis Inc., Genzyme Corporation. (Attachments: # (1) Exhibit A)(Czerwonka, Scott) |
| May 12, 2022 | 41 | Stipulation (8) Docket Text: Joint Stipulated Terms for Production of Electronically Stored Information and Proposed Order, by Aventis Inc., Genzyme Corporation. (Czerwonka, Scott) Modified on 5/13/2022 (nms). |
| May 9, 2022 | 40 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of (1) Novartis Gene Therapies, Inc. and Novartis Pharmaceuticals Corporation's First Set of Interrogatories to Plaintiffs (Nos. 1-13), and (2) Novartis Gene Therapies, Inc. and Novartis Pharmaceuticals Corporation's First Set of Requests for Production of Documents and Things to Plaintiffs (Nos. 1-51) filed by Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) |
| May 5, 2022 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Megan L. Meyers,Shannon Patrick for Novartis AG,Novartis Gene Therapies, Inc.,and Novartis Pharmaceuticals Corporation added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (apk) |
| May 3, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [39] STIPULATION and Proposed Order to Extend Time to submit a proposed protective order to May 9, 2022. Signed by Judge Richard G. Andrews on 5/3/2022. (nms) |
| May 2, 2022 | 39 | Stipulation to EXTEND Time (2) Docket Text: STIPULATION TO EXTEND TIME for the parties' to submit a proposed protective order to May 9, 2022 - filed by Novartis AG, Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) |
| Apr 29, 2022 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Daniel Gonzalez for Aventis Inc. and Genzyme Corporation added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) |
| Apr 27, 2022 | N/A | CORRECTING ENTRY: (0) Docket Text: CORRECTING ENTRY: The discovery filed at D.I. 36 has been removed from the docket per Local Rule 5.4(b). (nms) |
| Apr 27, 2022 | 38 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Plaintiffs' Rule 26(a)(1) Initial Disclosures filed by Aventis Inc., Genzyme Corporation.(Wilks, David) |
| Apr 26, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [34] MOTION for Pro Hac Vice Appearance of Attorney John E. Conour, Ph.D., filed by Aventis Inc., Genzyme Corporation, [35] MOTION for Pro Hac Vice Appearance of Attorney Daniel Gonzalez, Jr., filed by Aventis Inc., Genzyme Corporation. Signed by Judge Richard G. Andrews on 4/26/2022. (nms) |
| Apr 26, 2022 | 33 | Notice (Other) (1) Docket Text: NOTICE of Withdrawal of Pro Hac Vice Counsel, Nicole E. Grimm by Aventis Inc., Genzyme Corporation (Wilks, David) |
| Apr 26, 2022 | 34 | Motion for Leave to Appear Pro Hac Vice (3) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney John E. Conour, Ph.D. - filed by Aventis Inc., Genzyme Corporation. (Wilks, David) |
| Apr 26, 2022 | 35 | Motion for Leave to Appear Pro Hac Vice (3) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Daniel Gonzalez, Jr. - filed by Aventis Inc., Genzyme Corporation. (Wilks, David) |
| Apr 26, 2022 | 37 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Defendants' Rule 26(a)(1)(A) Disclosures filed by Novartis AG, Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) |
| Apr 25, 2022 | 32 | Answer to Counterclaim (29) Docket Text: ANSWER to [18] Answer to Amended Complaint, Counterclaim by Aventis Inc., Genzyme Corporation.(Wilks, David) |
| Apr 21, 2022 | 29 | Proposed Order (12) Docket Text: PROPOSED Scheduling Order, by Aventis Inc., Genzyme Corporation. (Wilks, David) Modified on 4/21/2022 (nms). |
| Apr 21, 2022 | 30 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Plaintiffs' First Set of Interrogatories and Plaintiffs' First Set of Requests for Production of Documents and Things filed by Aventis Inc., Genzyme Corporation.(Wilks, David) |
| Apr 21, 2022 | 31 | Scheduling Order (12) Docket Text: SCHEDULING ORDER: Joinder of Parties due by 11/30/2022. Amended Pleadings due by 11/30/2022. Fact Discovery completed by 3/31/2023. Dispositive Motions due by 9/30/2023. Answering Brief due 10/21/2023. Reply Brief due 11/4/2023. Joint Claim Construction Brief due by 12/8/2022. A Markman Hearing is set for 2/8/2023, at 9:00 AM in Courtroom 6A. A Pretrial Conference is set for 3/8/2024, at 8:30 AM in Courtroom 6A. A 5 day Jury Trial is set to start 3/25/2024, at 9:30 AM (see Order for further details). Signed by Judge Richard G. Andrews on 4/21/2022. (nms) Modified on 4/21/2022 (nms). |
| Apr 19, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [27] MOTION for Pro Hac Vice Appearance of Attorney Megan Meyers and Shannon Patrick, filed by Novartis AG, Novartis Pharmaceuticals Corporation, Novartis Gene Therapies, Inc.. Signed by Judge Richard G. Andrews on 4/19/2022. (nms) |
| Apr 18, 2022 | N/A | Oral Order (0) Docket Text: ORAL ORDER: The Rule 16(b) Conference scheduled for 4/19/2022, is CANCELED. The parties are to resubmit the proposed scheduling order by 4/21/2022, consistent with the edits the Court has made (and provided via email to Local Counsel) and agree to all other interim dates jointly. Ordered by Judge Richard G. Andrews on 4/18/2022. (nms) |
| Apr 18, 2022 | 27 | Motion for Leave to Appear Pro Hac Vice (4) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Megan Meyers and Shannon Patrick - filed by Novartis AG, Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Apr 18, 2022 | 28 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Plaintiffs Disclosures under Paragraph 4(a) of the Default Standard for Discovery filed by Aventis Inc., Genzyme Corporation.(Wilks, David) |
| Apr 14, 2022 | 25 | Proposed Order (16) Docket Text: PROPOSED Scheduling Order, by Aventis Inc., Genzyme Corporation. (Wilks, David) Modified on 4/14/2022 (nms). |
| Apr 12, 2022 | 24 | Letter (1) Docket Text: Letter to the Honorable Richard G. Andrews, from David E. Wilks, regarding dial-in information for the Rule 16(b) Telephone Conference. (Wilks, David) Modified on 4/12/2022 (nms). |
| Apr 6, 2022 | 23 | Order Setting Scheduling Conference (1) Docket Text: Order Setting Rule 16(b) Telephone Conference: A Scheduling Conference is set for 4/19/2022, at 2:00 PM before Judge Richard G. Andrews (see Order for further details). Signed by Judge Richard G. Andrews on 4/6/2022. (nms) |
| Apr 5, 2022 | 22 | Notice of Appearance (1) Docket Text: NOTICE of Appearance by Alexandra M. Joyce on behalf of Novartis AG, Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation (Joyce, Alexandra) |
| Apr 4, 2022 | 18 | Answer to Amended Complaint (30) Docket Text: ANSWER to [17] Amended Complaint, and COUNTERCLAIMS against Aventis Inc., Genzyme Corporation, by Novartis Pharmaceuticals Corporation, Novartis Gene Therapies, Inc., Novartis AG.(Silver, Daniel) Modified on 4/5/2022 (nms). |
| Apr 4, 2022 | 19 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Novartis AG. (Silver, Daniel) |
| Apr 4, 2022 | 20 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Novartis AG for Novartis Gene Therapies, Inc. filed by Novartis Gene Therapies, Inc.. (Silver, Daniel) |
| Apr 4, 2022 | 21 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Novartis AG for Novartis Pharmaceuticals Corporation filed by Novartis AG, Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Feb 23, 2022 | 17 | Amended Complaint* (1) |
| Feb 23, 2022 | 17 | Amended Complaint (Main Document) (21) Docket Text: FIRST Amended Complaint against Novartis AG, Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation - filed by Genzyme Corporation, Aventis Inc.. (Attachments: # (1) Exhibit A, # (2) Exhibit B, # (3) Exhibit C, # (4) Exhibit D, # (5) Exhibit E, # (6) Exhibit F, # (7) Exhibit G)(Wilks, David) Modified on 2/24/2022 (nms). |
| Feb 23, 2022 | 17 | Amended Complaint (Exhibit A) (13) Docket Text: FIRST Amended Complaint against Novartis AG, Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation - filed by Genzyme Corporation, Aventis Inc.. (Attachments: # (1) Exhibit A, # (2) Exhibit B, # (3) Exhibit C, # (4) Exhibit D, # (5) Exhibit E, # (6) Exhibit F, # (7) Exhibit G)(Wilks, David) Modified on 2/24/2022 (nms). |
| Feb 23, 2022 | 17 | Amended Complaint (Exhibit B) (30) Docket Text: FIRST Amended Complaint against Novartis AG, Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation - filed by Genzyme Corporation, Aventis Inc.. (Attachments: # (1) Exhibit A, # (2) Exhibit B, # (3) Exhibit C, # (4) Exhibit D, # (5) Exhibit E, # (6) Exhibit F, # (7) Exhibit G)(Wilks, David) Modified on 2/24/2022 (nms). |
| Feb 23, 2022 | 17 | Amended Complaint (Exhibit C) (30) Docket Text: FIRST Amended Complaint against Novartis AG, Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation - filed by Genzyme Corporation, Aventis Inc.. (Attachments: # (1) Exhibit A, # (2) Exhibit B, # (3) Exhibit C, # (4) Exhibit D, # (5) Exhibit E, # (6) Exhibit F, # (7) Exhibit G)(Wilks, David) Modified on 2/24/2022 (nms). |
| Feb 23, 2022 | 17 | Amended Complaint (Exhibit D) (30) Docket Text: FIRST Amended Complaint against Novartis AG, Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation - filed by Genzyme Corporation, Aventis Inc.. (Attachments: # (1) Exhibit A, # (2) Exhibit B, # (3) Exhibit C, # (4) Exhibit D, # (5) Exhibit E, # (6) Exhibit F, # (7) Exhibit G)(Wilks, David) Modified on 2/24/2022 (nms). |
| Feb 23, 2022 | 17 | Amended Complaint (Exhibit E) (30) Docket Text: FIRST Amended Complaint against Novartis AG, Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation - filed by Genzyme Corporation, Aventis Inc.. (Attachments: # (1) Exhibit A, # (2) Exhibit B, # (3) Exhibit C, # (4) Exhibit D, # (5) Exhibit E, # (6) Exhibit F, # (7) Exhibit G)(Wilks, David) Modified on 2/24/2022 (nms). |
| Feb 23, 2022 | 17 | Amended Complaint (Exhibit F) (30) Docket Text: FIRST Amended Complaint against Novartis AG, Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation - filed by Genzyme Corporation, Aventis Inc.. (Attachments: # (1) Exhibit A, # (2) Exhibit B, # (3) Exhibit C, # (4) Exhibit D, # (5) Exhibit E, # (6) Exhibit F, # (7) Exhibit G)(Wilks, David) Modified on 2/24/2022 (nms). |
| Feb 23, 2022 | 17 | Amended Complaint (Exhibit G) (13) Docket Text: FIRST Amended Complaint against Novartis AG, Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation - filed by Genzyme Corporation, Aventis Inc.. (Attachments: # (1) Exhibit A, # (2) Exhibit B, # (3) Exhibit C, # (4) Exhibit D, # (5) Exhibit E, # (6) Exhibit F, # (7) Exhibit G)(Wilks, David) Modified on 2/24/2022 (nms). |
| Jan 7, 2022 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorneys Michael R. Galgano, Cora R. Holt, John D. Livingstone, and Amanda K. Murphy for Novartis AG, Novartis Gene Therapies, Inc.,and Novartis Pharmaceuticals Corporation added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (srs) |
| Jan 5, 2022 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorneys Bryan G. Helwig, Nicole E. Grimm, George T. Lyons, III, Paul H. Berghoff, Joshua R. Rich, and Alexandra E. MacKenzie for Aventis Inc., and Genzyme Corporation added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (twk) |
| Jan 5, 2022 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Bryan G. Helwig, Joshua R. Rich, Paul H. Berghoff, Alexandra E. MacKenzie, Nicole E. Grimm, and George T. Lyons, III for Aventis Inc. and Genzyme Corporation added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mal) |
| Jan 5, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [16] MOTION for Pro Hac Vice Appearance of Attorney John Livingstone, Amanda Murphy, Ph.D., Cora Holt, and Michael Galgano, filed by Novartis AG, Novartis Pharmaceuticals Corporation, Novartis Gene Therapies, Inc.. Signed by Judge Richard G. Andrews on 1/5/2022. (nms) |
| Jan 5, 2022 | 16 | Motion for Leave to Appear Pro Hac Vice (6) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney John Livingstone, Amanda Murphy, Ph.D., Cora Holt, and Michael Galgano - filed by Novartis AG, Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Jan 4, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [9] MOTION for Pro Hac Vice Appearance of Attorney Paul H. Berghoff, filed by Aventis Inc., Genzyme Corporation. Signed by Judge Richard G. Andrews on 1/4/2022. (nms) |
| Jan 4, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [14] MOTION for Pro Hac Vice Appearance of Attorney Alexandra E. MacKenzie, filed by Aventis Inc., Genzyme Corporation, [12] MOTION for Pro Hac Vice Appearance of Attorney George T. Lyons, III, filed by Aventis Inc., Genzyme Corporation, [13] MOTION for Pro Hac Vice Appearance of Attorney Bryan G. Helwig, Ph.D, filed by Aventis Inc., Genzyme Corporation, [11] MOTION for Pro Hac Vice Appearance of Attorney Nicole E. Grimm, filed by Aventis Inc., Genzyme Corporation, and [10] MOTION for Pro Hac Vice Appearance of Attorney Joshua R. Rich, filed by Aventis Inc., Genzyme Corporation. Signed by Judge Richard G. Andrews on 1/4/2022. (nms) |
| Jan 4, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [15] STIPULATION and Proposed Order to Extend Time (*Reset Answer Deadlines: Novartis AG answer due 4/4/2022; Novartis Gene Therapies, Inc. answer due 4/4/2022; Novartis Pharmaceuticals Corporation answer due 4/4/2022). Signed by Judge Richard G. Andrews on 1/4/2022. (nms) |
| Jan 4, 2022 | 8 | Waiver of Service Executed (1) Docket Text: WAIVER OF SERVICE returned executed by Genzyme Corporation, Aventis Inc.: For Novartis AG waiver sent on 1/3/2022, answer due 3/4/2022. (Wilks, David) |
| Jan 4, 2022 | 9 | Motion for Leave to Appear Pro Hac Vice (3) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Paul H. Berghoff - filed by Aventis Inc., Genzyme Corporation. (Wilks, David) |
| Jan 4, 2022 | 10 | Motion for Leave to Appear Pro Hac Vice (3) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Joshua R. Rich - filed by Aventis Inc., Genzyme Corporation. (Wilks, David) |
| Jan 4, 2022 | 11 | Motion for Leave to Appear Pro Hac Vice (3) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Nicole E. Grimm - filed by Aventis Inc., Genzyme Corporation. (Wilks, David) |
| Jan 4, 2022 | 12 | Motion for Leave to Appear Pro Hac Vice (3) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney George T. Lyons, III - filed by Aventis Inc., Genzyme Corporation. (Wilks, David) |
| Jan 4, 2022 | 13 | Motion for Leave to Appear Pro Hac Vice (3) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Bryan G. Helwig, Ph.D - filed by Aventis Inc., Genzyme Corporation. (Wilks, David) |
| Jan 4, 2022 | 14 | Motion for Leave to Appear Pro Hac Vice (3) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Alexandra E. MacKenzie - filed by Aventis Inc., Genzyme Corporation. (Wilks, David) |
| Jan 4, 2022 | 15 | Stipulation to EXTEND Time (2) Docket Text: STIPULATION TO EXTEND TIME to move, answer, or otherwise respond to Complaint to April 4, 2022 - filed by Novartis AG, Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Jan 3, 2022 | 7 | Notice of Appearance (1) Docket Text: NOTICE of Appearance by Daniel M. Silver on behalf of Novartis AG, Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation (Silver, Daniel) |
| Dec 16, 2021 | 5 | Summons Returned Executed (2) Docket Text: SUMMONS Returned Executed by Genzyme Corporation, Aventis Inc.. Novartis Gene Therapies, Inc. served on 12/15/2021, answer due 1/5/2022. (Wilks, David) |
| Dec 16, 2021 | 6 | Summons Returned Executed (2) Docket Text: SUMMONS Returned Executed by Genzyme Corporation, Aventis Inc.. Novartis Pharmaceuticals Corporation served on 12/15/2021, answer due 1/5/2022. (Wilks, David) |
| Dec 15, 2021 | N/A | Case Assigned/Reassigned (0) Docket Text: Case Assigned to Judge Richard G. Andrews. Please include the initials of the Judge (RGA) after the case number on all documents filed. (rjb) |
| Dec 10, 2021 | N/A | No Summons Issued (0) Docket Text: No Summons Issued. (myr) |
| Dec 10, 2021 | 1 | Complaint (Main Document) (18) Docket Text: COMPLAINT filed with Jury Demand against Novartis AG, Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation - Magistrate Consent Notice to Pltf. ( Filing fee $ 402, receipt number ADEDC-3760297.) - filed by Genzyme Corporation, Aventis Inc. (Attachments: # (1) Exhibit A, # (2) Exhibit B, # (3) Exhibit C, # (4) Exhibit D, # (5) Exhibit E, # (6) Exhibit F, # (7) Civil Cover Sheet)(myr) |
| Dec 10, 2021 | 1 | Complaint (Exhibit A) (13) Docket Text: COMPLAINT filed with Jury Demand against Novartis AG, Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation - Magistrate Consent Notice to Pltf. ( Filing fee $ 402, receipt number ADEDC-3760297.) - filed by Genzyme Corporation, Aventis Inc. (Attachments: # (1) Exhibit A, # (2) Exhibit B, # (3) Exhibit C, # (4) Exhibit D, # (5) Exhibit E, # (6) Exhibit F, # (7) Civil Cover Sheet)(myr) |
| Dec 10, 2021 | 1 | Complaint (Exhibit B) (30) Docket Text: COMPLAINT filed with Jury Demand against Novartis AG, Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation - Magistrate Consent Notice to Pltf. ( Filing fee $ 402, receipt number ADEDC-3760297.) - filed by Genzyme Corporation, Aventis Inc. (Attachments: # (1) Exhibit A, # (2) Exhibit B, # (3) Exhibit C, # (4) Exhibit D, # (5) Exhibit E, # (6) Exhibit F, # (7) Civil Cover Sheet)(myr) |
| Dec 10, 2021 | 1 | Complaint (Exhibit C) (30) Docket Text: COMPLAINT filed with Jury Demand against Novartis AG, Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation - Magistrate Consent Notice to Pltf. ( Filing fee $ 402, receipt number ADEDC-3760297.) - filed by Genzyme Corporation, Aventis Inc. (Attachments: # (1) Exhibit A, # (2) Exhibit B, # (3) Exhibit C, # (4) Exhibit D, # (5) Exhibit E, # (6) Exhibit F, # (7) Civil Cover Sheet)(myr) |
| Dec 10, 2021 | 1 | Complaint (Exhibit D) (30) Docket Text: COMPLAINT filed with Jury Demand against Novartis AG, Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation - Magistrate Consent Notice to Pltf. ( Filing fee $ 402, receipt number ADEDC-3760297.) - filed by Genzyme Corporation, Aventis Inc. (Attachments: # (1) Exhibit A, # (2) Exhibit B, # (3) Exhibit C, # (4) Exhibit D, # (5) Exhibit E, # (6) Exhibit F, # (7) Civil Cover Sheet)(myr) |
| Dec 10, 2021 | 1 | Complaint (Exhibit E) (30) Docket Text: COMPLAINT filed with Jury Demand against Novartis AG, Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation - Magistrate Consent Notice to Pltf. ( Filing fee $ 402, receipt number ADEDC-3760297.) - filed by Genzyme Corporation, Aventis Inc. (Attachments: # (1) Exhibit A, # (2) Exhibit B, # (3) Exhibit C, # (4) Exhibit D, # (5) Exhibit E, # (6) Exhibit F, # (7) Civil Cover Sheet)(myr) |
| Dec 10, 2021 | 1 | Complaint (Civil Cover Sheet F) (30) Docket Text: COMPLAINT filed with Jury Demand against Novartis AG, Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation - Magistrate Consent Notice to Pltf. ( Filing fee $ 402, receipt number ADEDC-3760297.) - filed by Genzyme Corporation, Aventis Inc. (Attachments: # (1) Exhibit A, # (2) Exhibit B, # (3) Exhibit C, # (4) Exhibit D, # (5) Exhibit E, # (6) Exhibit F, # (7) Civil Cover Sheet)(myr) |
| Dec 10, 2021 | 1 | Complaint (Civil Cover Sheet) (1) Docket Text: COMPLAINT filed with Jury Demand against Novartis AG, Novartis Gene Therapies, Inc., Novartis Pharmaceuticals Corporation - Magistrate Consent Notice to Pltf. ( Filing fee $ 402, receipt number ADEDC-3760297.) - filed by Genzyme Corporation, Aventis Inc. (Attachments: # (1) Exhibit A, # (2) Exhibit B, # (3) Exhibit C, # (4) Exhibit D, # (5) Exhibit E, # (6) Exhibit F, # (7) Civil Cover Sheet)(myr) |
| Dec 10, 2021 | 2 | Magistrate Consent Forms (3) Docket Text: Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (myr) |
| Dec 10, 2021 | 3 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Sanofi for Aventis Inc., Genzyme Corporation filed by Aventis Inc., Genzyme Corporation. (Wilks, David) |
| Dec 10, 2021 | 4 | Patent/Trademark Report to Commissioner (1) Docket Text: Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,596,535 ;7,125,717 ;7,785,888 ;7,846,729 ;8,093,054. (nmg) |
